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Abstract 
 
Thermoplastic polyurethanes (TPUs) are widely used in biomedical applications due to 
their excellent mechanical properties and biocompatibility. Their roles as matrices to 
incorporate therapeutics have been investigated in different areas. With the advance of 
peptides as therapeutics, there is critical need for investigating delivery of peptides using 
drug delivery systems. However, there is little work on understanding the release of 
peptides from TPUs. The aim of this study is to understand how therapeutic peptides might 
be incorporated and released from TPUs.  
 
Initially, we compared the effect of supercritical carbon dioxide treatment and solvent 
casting on the loading and release of model drugs from polyurethane films. We found that 
scCO2 treatment may cause a shift of hard segment to the surface of film, but this 
treatment did not significantly affect physical properties of TPUs. This rearrangement of 
hard segment caused by scCO2 may affect drug release. We then examined the loading 
and release of 3 model drugs using scCO2 and compared with solvent casting. ScCO2 was 
able to load all these 3 model drugs consistently and homogeneously into the films, and 
the release of these 3 drugs was qualitatively similar by scCO2 or solvent casting. 
However, the amount of drug accumulated in the films by scCO2 was much less than the 
total amount of drug in the reaction vessel. This could be a practical limitation for 
therapeutics such as peptides that are expensive to synthesise. In addition, we found the 
composition of hard and soft segments may contribute greatly to the efflux of drugs. 
 
On the basis of these results, we next investigated the in vitro efflux of peptides from 
polyurethane films by solvent casting. Interestingly, we found there was a correlation 
between cumulative release and molecular weight of the peptides. Because one of the 
causes of implant failure is localised inflammation, we were specifically interested in the 
delivery of C5aR antagonists from TPU films. First, we found that cyclic peptides may be 
more stable under harsh casting conditions (elevated temperatures, organic solvents) 
compared to the linear peptides. Mild conditions are required to retain the bioactivity of 
peptides. Interestingly, similar to the efflux results of model drugs, the release profiles of 
peptides were also dependent on the composition of hard and soft segments of TPUs.  We 
also found serum proteins in the medium could facilitate the release of peptides. In 
addition, in vitro bioactivity of the released peptides was examined by measuring 
intercellular Ca2+ concentration mobilization in a cell model of C5a receptor signaling. The 
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results demonstrate that released peptides retained their bioactivity. To better control the 
efflux of peptides, we examined blending of different TPUs. We found that the initial rate 
and extent of drug released from Tecoflex 80A was significant suppressed by increasing 
the amount of ElastEon 5325 in the blend. These results offer a simple approach for 
controlling drug release from TPUs.  
 
Further studies were conducted to understand how the peptide delivery systems we 
developed could improve the in vivo pharmacokinetics and pharmacodynamics of PMX53, 
an anti-inflammatory cyclic peptide that targets the C5a receptor. While the peptide shows 
rapid clearance from the blood (half-life < 30 min), the blended TPU films were able to 
prolong the plasma level of PMX53 for up to 9 days. In addition, PMX53 released from this 
system was able to impair in vivo melanoma B16-F10 tumor growth, a previously reported 
effect of anti-inflammatories. In conclusion, the TPU-based peptide delivery systems we 
developed show great potential for future clinical drug delivery applications. Moreover, the 
novel approach presented here may improve the pharmacological utility of some peptides 
as therapeutics. 
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Chapter 1  
Introduction  
 
 
 
 
 
 
 
 
 
1.1 Implantable drug delivery systems 
Biomaterials are generally defined as natural or synthetic materials that are used alone or as part of a 
complex system to direct interact with biological systems (Williams 2009). Such materials possess 
different chemical, mechanical and physical properties, which are desirable for their use in 
therapeutic and diagnostic applications. Many materials, such as metals, polymers, and ceramics, 
can be used as biomaterials. Among these three major categories, polymers are the most widely used 
(Kariduraganavar, Kittur et al. 2014). The use of biomaterials has become an increasingly important 
area in current medical applications. Nevertheless, for the long-term use of biomaterials, 
biocompatibility remains a critical issue in limiting their applications. Biocompatibility of a 
biomaterial can be described as the ability of the material to perform its intended function without 
eliciting any undesirable local or systemic effects in the host (Williams 2008). This can be a two-
way interaction that includes the effect of the biological environment on the implanted material, and 
the effect of the material and its break down products on the biological systems (Brown 1999). 
Despite the huge range of clinical applications of classical devices, challenges with their longevity 
and their ability to be fully accepted in the host still limit their applications. For instance, synthetic 
Gortex® and Dacron® have been used with great success as vascular conduits, however, problems 
such as foreign body reaction, thrombosis, and long-term stability still need to be overcome 
(Mascarenhas and MacDonald 2008). Many strategies have been developed to mediate and enhance 
10 
 
the biocompatibility of devices or implants, such as changing the chemical properties of a surface 
(Tang, Santerre et al. 1997) and polymer coating (Bridges and García 2008).  
 
1.1.1 Introduction of implantable drug delivery systems 
The activity of pharmaceutical agents is limited by many factors, such as degradation, non-specific 
interaction with other cells and rapid clearance (Gemma, Judit et al. 2012). With the growth in drug 
discovery, the need for innovative methods of administration to prolong therapeutic effect has risen. 
Among these methods, polymeric drug delivery systems are of great interest. Drug delivery systems 
are engineered technologies for loading and releasing a drug in a predetermined manner to maintain 
the drug level for a defined time period or targeting a specific site in the body (López-Periago, 
Argemí et al. 2009). Compared with conventional oral or intravascular/intramuscular administration 
of drug, these so-called “smart” or “intelligent” systems are designed to control drug release 
kinetics, enhance drug solubility, prolong bioactivity, improve drug efficacy, decrease the high dose 
administration and overcome toxic side effects (Kleiner, Wright et al. 2014). In addition, these 
systems can improve patient compliance due to less frequent drug administration and the avoidance 
of systemic circulation of drugs (Wolinsky, Colson et al. 2012). The implantable drug delivery 
systems can be used alone to directly deliver therapeutics at the site of disease, or combined with 
other implanted devices to create multifunction devices. This strategy can be applied to treat 
multiple diseases, including inflammation, infection, and cancer therapy. 
 
Implantable devices delivering therapeutic agents in a controlled manner have been widely 
investigated due to their considerable clinical impact on aiding host integration and inhibiting 
undesirable host responses. Research into implantable drug delivery systems originated in the 1960s, 
when silicones were used by Folkman to control drug release and prolong systemic drug 
administration based on the diffusion of small molecules (Folkman and Long 1964, Folkman, Long 
et al. 1966). In 1990, the approval of the device Norplant® by the FDA accelerated the developing 
implantable drug delivery systems (Kleiner, Wright et al. 2014). The increase in the number of 
commercialized products shows the great potential of implanted drug delivery systems. Although 
considerable effort has been made since the beginning, the progress to commercialise safe and 
effective drug-loaded implants has been slow. It is difficult for many experimental systems to enter 
the clinic. Some of the major problems that need to be overcome include stability, reproducibility, 
toxicity, and lack of biocompatibility (Kleiner, Wright et al. 2014). Nevertheless, several 
implantable drug delivery systems have been commercial available including non-degradable and 
biodegradable systems. Devices, such as Cypher sirolimus-eluting stent (Schampaert, Moses et al. 
2006) and Norplant® containing hormonal levonorgestrel (Munro, Laughlin et al. 1996), have been 
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approved by USFDA and have shown practical clinical properties. Drugs released from these 
devices were controlled by diffusion. However, these non-degradable systems have been shown 
correlation to inflammatory responses and local toxicity in clinical applications. To avoid the need 
to remove devices after implantation, biodegradable polymers for drug delivery application have 
become increasingly popular. The Biomatrix (Biosensors international Ltd) stent, for example, is a 
biolimus A9-eluting stent, containing polylactic acid on the abluminal surface. Polylactic acid 
converts to lactic acid within 6 to 9 months with slow release of biolimus A9 (Abizaid and Costa 
2010). However, compared to Cypher, this system failed to show any improvement in regard to 
adverse events, especially thrombosis (Abizaid and Costa 2010). These examples demonstrate that 
biocompatibility of implantable drug delivery systems remains a critical issue in limiting their 
clinical applications, which drives the demanding for novel or improved drug delivery systems.  
 
There are many strategies for incorporating therapeutics into polymeric support materials, including 
encapsulation of drugs into a carrier (Miladi, Sfar et al. 2013), adsorption of drugs onto the support 
materials by immersing materials in drug solutions (Mouriño and Boccaccini 2010), and manual 
mixing the drug and material solutions. However, conventional techniques show many limitations 
due to the involvement of organic solvents (Jung, Haam et al. 2012). The interest in cleaner 
approaches such as using environmental friendly solvents is increasing. In this field, supercritical 
processes, especially using carbon dioxide (CO2) as a carrier medium, are of great interest due to 
their mild conditions, low toxicity, nonflammable, and no residual solvents in the end products 
(López-Periago, Argemí et al. 2009, Jung, Haam et al. 2012). In addition, supercritical carbon 
dioxide (scCO2) technology can retain drug activity (López-Periago, Argemí et al. 2009). Due to 
these advantages, supercritical processes have shown great potential for preparing therapeutic 
proteins/peptides delivery systems. Campardelli et al has shown the feasibility of using supercritical 
carbon dioxide to synthesize biodegradable microspheres poly(glycolic acid) for the release of 
proteins and peptides, such as bovine serum albumin and insulin like growth factor (h-IGF) 
(Campardelli, Reverchon et al. 2012). However, during the last decade, research using supercritical 
carbon dioxide has been limited to producing biodegradable microparticles and nanoparticles to 
encapsulate peptides or proteins. Very little work has been published using it as solvent to dissolve 
peptides or proteins and carry them into biostable polymer films. In addition only a few products 
using supercritical processes have been commercialized.  
 
Due to the versatility of implantable drug delivery systems, a variety of therapeutic compounds, 
ranging from classic small molecule drugs to large molecule DNA and proteins, can benefit from 
these systems. Among these compounds, peptides are especially attractive drug candidates due to 
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their low inherent toxicity, high potency and selectivity, and size advantages over proteins (Lalatsa, 
Schatzlein et al. 2014). However, many obstacles limit using peptides as potential drugs, including 
poor physical and metabolic stability, limited biomembrane permeability, short therapeutic effect, 
and rapid elimination. Delivery of peptides using polymeric matrices has shown great potential in 
converting peptides into medicines. For example, a peptide delivery strategy with a hydrophilic 
peptide, Leucine5-enkephalin, encapsulated within chitosan amphiphile nanoparticles enabled an 
increase in peptides brain levels and stabilized peptide in the plasma (Lalatsa, Lee et al. 2012). 
However, for peptide-polymer delivery systems, controlled release and retaining stability during 
synthesis of the peptide-polymer complex are still challenges and there are very few peptide 
delivery systems in clinical trials. There is a need for suitable delivery strategies that would enhance 
peptide stability and improve the therapeutic effect in a controlled manner.  
 
1.1.2 Mechanisms of drug release from polymeric medical devices 
To design an appropriate drug delivery system, the mechanisms of drug release kinetics should be 
investigated to optimize its efficacy. Drug release from a polymeric matrix refers to a process in 
which the drug migrates from the polymeric matrix into the surrounding medium (Cherng, Hou et al. 
2013). Many factors contribute to the drug release kinetics, such as characteristics of the material 
matrix, the release environment and drug properties (Fu and Kao 2010). Table 1.1 summarises the 
mechanisms of drug release. For non-degradable polymeric matrices, the main transport 
phenomenon for drug release is diffusion. Non-degradable polymers can be made into a reservoir 
(Table 1.1 A) or a matrix type material (Table 1.1 B). For biodegradable polymeric delivery 
systems, drug release occurs primarily via various physical processes, including diffusion, 
polymeric degradation (Table 1.1 C), and polymeric swelling (Table 1.1 D). Other important 
physical processes need to be considered including the cleavage of drug from polymer by 
hydrolysis or different enzymes (Table 1.1 E) and pore formation (Table 1.1 F). Many well-
established mathematical models for modeling drug release kinetics are listed in Table 1.2. 
Understanding these mechanisms of drug release provides great value for the optimal design of 
drug delivery systems. 
 
In diffusion-controlled systems, drugs are normally encapsulated into a non-swollen or fully 
swollen reservoir or mixed homogeneously in a simple monolithic polymer matrix. In these systems, 
diffusion occurs slowly compared to the rate of drug dissociation. The rate of drug release can be 
controlled by adjusting the physical characteristics of devices, such as increasing the thickness 
(Folkman, Long et al. 1966), changing the pore sizes (Tanaka, Matsumura et al. 1984), and 
changing the shape (Ritger and Peppas 1987). One clinically used non-degradable drug delivery 
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devices is TAXUSTM paclitaxel eluting stent (Kamath, Barry et al. 2006). It is a monolithic system 
where paclitaxel is released to the physiological medium by diffusion through the polymeric matrix. 
In diffusion-controlled systems, drug release can be represented by many mathematical models 
(Table 1.2). Among these models, the Higuchi equation (Table 1.2) provides a simple model for 
illustrating diffusion controlled release (Higuchi 1961, Higuchi 1963). This model is based on the 
main hypotheses that drug diffusion occurs only in one dimension, and matrix swelling and 
dissolution are negligible. 
 
For biodegradable systems, degradation and erosion of polymers occur by interaction with 
surrounding fluids (Liechty, Kryscio et al. 2010). Degradation of polymers can occur on the surface 
or throughout the whole material (Kearney and Mooney 2013). Drugs can be loaded into 
biodegradable systems by encapsulation into a polymeric membrane (Fattahi, Borhan et al. 2013), 
mixing with polymer solution during casting (Huang, Steele et al. 2013), or embedding of drug into 
polymer chains during polymerization (Duncan, Gac-Breton et al. 2001). Mechanisms of drug 
release, including dissolution, hydrolytic cleavage and enzymatic degradation, contribute to the 
release kinetics. Several biodegradable polymers have been developed as main component of 
implantable drug delivery systems. An example is Gliadel® wafer (Perry and Schmidt 2006), which 
is designed to deliver carmustine for glioblastoma treatment. It consists of a biodegradable 
copolymer polifeprosan, which has poly [bis (p-carboxyphenoxy)] propane and sebacic acid in a 
20:80 molar ratio, and carmustine , which is distributed evenly in the polifeprosan matrix. When 
exposed to the aqueous environment, the anhydride bonds in the copolymer are hydrolyzed to 
release carmustine. A well-known issue for biodegradable systems is the safety of degradation 
products, as polymer degradation products may be toxic or initiate adverse responses in host.  
 
In swelling-controlled systems, drugs are loaded into hydrophilic polymer matrices. For instance, 
Methocel® cellulose ethers are widely used as swellable polymers in controlled drug delivery 
systems (Escudero, Ferrero et al. 2010). Once exposed to an aqueous environment, the polymer 
matrices are able to swell by adsorbing surrounding fluids (Liechty, Kryscio et al. 2010). The 
penetration of fluids can increase the mobility of polymer chains. The Korsmeyer-Peppas model 
(Table 1.2) can be used to describe these swelling-controlled systems (Korsmeyer, Gurny et al. 
1983). When diffusion is slow compared to the rate of chain relaxation, the system is diffusion 
controlled. The release exponent n is equal to 0.5. Fick’s law of diffusion provides the fundamental 
description for drug release from this system. However, when the polymer relaxation time is similar 
to the diffusion time (0.5 < n < 1), drug release becomes non-fickian diffusion. Many models can 
also be used to describe non-fickian diffusion, such as Avrami, Peppas-Sahlin, and Alfrey (Table 
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1.2). When the rate of chain relaxation is the limiting step (n = 1), the system is swelling controlled. 
Drug release from this system follows case II transport. 
Table 1.1 Summary of mechanisms of drug release. Adapt from (Langer 1990) 
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Table 1.2 Summary of several mathematical models for drug release 
Model Expression Application Reference 
Higuchi 
𝑀𝑡
𝑀∞
= 𝑘𝑡
1
2 Fickian diffusion (Higuchi 1961, Higuchi 1963) 
Weibull 
𝑀𝑡
𝑀∞
= 1 − 𝑒−
(𝑡−𝑇)𝑏
𝑎  
b=1, exponential profile; 
b>1, sigmoidal with a turning point; 
b<1, a steeper increase exponential profile 
(Dash, Murthy et al. 2010) 
Korsmeyer-Peppas 
𝑀𝑡
𝑀∞
= 𝑘𝑡𝑛 
n=0.5, fickian diffusion; 
n=1, case II transport; 
0.5<n<1, non-fickian diffusion 
(Korsmeyer, Gurny et al. 
1983) 
Avrami 
𝑀𝑡
𝑀∞
= 1 − 𝑒−𝑘𝑡
𝑛
 Non-fickian diffusion 
(Jokanović, Čolović et al. 
2013) 
Peppas-Sahlin 
𝑀𝑡
𝑀∞
= 𝑘1𝑡
𝑚 + 𝑘2𝑡
2𝑚 Non-fickian diffusion (Peppas and Sahlin 1989) 
Alfrey 
𝑀𝑡
𝑀∞
= 𝑘1𝑡 + 𝑘2𝑡
1
2 Non-fickian diffusion (Sigmoid) (Alfrey, Gurnee et al. 1966) 
Zero order 
𝑀𝑡
𝑀∞
= 𝑘𝑑𝑡 Case II transport (Serra, Doménech et al. 2006) 
 
Parameter definitions: Mt = amount of drug released by time t; M∞ = total mass of drug; k, k1, k2, kd, a = efflux rate constants; n, m = release exponent.  
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In affinity-controlled systems, therapeutic agents are loaded into polymer matrices due to the strong 
and reversible interaction of drugs with polymer matrices. The drug release can be controlled based 
on the interaction between the drug and the matrix, such as hydrophobic interaction, covalent 
bonding, hydrogen bonding, ionic bonding and Van der Waals forces (Kearney and Mooney 2013). 
Various heparin-binding delivery systems, for example, have been used for affinity-controlled 
release of proteins, including vascular endothelial growth factor, basic fibroblast growth factor 
(Pike, Cai et al. 2006) and beta-nerve growth factor (Sakiyama-Elbert and Hubbell 2000). Heparin 
was incorporated into these polymeric gels to regulate release of heparin-binding proteins. In these 
systems, increasing or decreasing the affinity between molecules can lead to changes of release rate. 
The release of drugs can be stimulated by many physical conditions, such as pH or temperature 
changes (Wang, Gao et al. 2013), enzyme degradation (Cherng, Hou et al. 2013), light (Liechty, 
Kryscio et al. 2010), and magnetic field or ultrasound (Alvarez-Lorenzo and Concheiro 2014). For 
example, Kim et al developed a controlled release system consisting of mesoporous silica as the 
drug reservoir and polydimethylsiloxane as an implantable device. The release of small drug 
ibuprofen from this non-erodible polymer system could be triggered by ultrasound (Kim, Matsuda 
et al. 2006).  
 
From above, it appears that mathematical modeling plays an important role in understanding the 
mechanism of drug release from polymer matrices. The purpose of mathematical modeling is to  
support the assumptions, which provide further insight into the system.  
 
1.1.3 Pharmacokinetics of drug release from polymeric medical devices 
Conventional methods of drug administration rely on oral administration, intravenous, 
intramuscular or subcutaneous injection. These routes of drug administration often have short 
plasma residence time, inadequate distribution to the target site, rapid metabolism and renal 
clearance, and side effects due to off-target exposure (Chertok, Webber et al. 2013). Each drug has 
a therapeutic range which is above the minimum effective concentration and below minimum toxic 
concentration (Shargel, Wu-Pong et al. 2005). With the advance of polymeric-based drug delivery 
systems, pharmacokinetic evaluation, which is a mathematical description of the in vivo fate of drug 
(Jambhekar, Breen et al. 2012), has gained much attention. A drug delivery system requires 
understanding of its pharmacokinetics, including absorption, distribution, metabolism, and 
excretion, from the early stage of the system design (Hamidi, Azadi et al. 2013), which may later 
help clinicians apply that knowledge to patient treatment (Duncan and Spreafico 1994, Lin and Lu 
1997). Sustained drug delivery systems aim to maintain the drug plasma level or a drug 
concentration in target tissue within the desired therapeutic range over an extended time to improve 
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the efficacy of the drug (Liechty, Kryscio et al. 2010). In addition, in vitro release kinetics may be 
modified in diseased states, or as a consequence of host responses to foreign materials. Therefore, 
investigating the physiological pharmacokinetics and pharmacologic responses of a drug delivery 
system plays an important role in designing new or improved delivery systems. 
 
The in vivo fate of a drug can be described as shown in Figure 1.1. Once a drug is released from a 
polymer matrix, it penetrates different physiological barriers to enter the systemic circulation, 
distributes to tissues, and undergoes elimination and metabolism (Chertok, Webber et al. 2013). 
Table 1.3 shows the plasma level-time curve obtained by different methods of administration.  
Single dose administration of a drug can achieve rapid therapeutic concentration and rapid 
elimination (Table 1.3 A). Table 1.3 B shows the plasma level-time curve of a drug given by 
constant IV infusion or zero order drug delivery. The drug level rises from time zero to a steady-
state, where the rate of drug removed is equal to the rate of drug delivery (Table 1.3B).  In a chronic 
treatment regimen, multiple doses are administrated at regular intervals to maintain a therapeutic 
effect (Table 1.3C). The curve in Table 1.3C can be achieved by repeated dose injection or pulsatile 
drug delivery system. For example, Prescott et al developed a controlled pulsatile release of the 
polypeptide leuprolide from microchip implants over 6 months. The pulsatile release could be 
controlled by telemetry (Prescott, Lipka et al. 2006). The extended release profile from a polymer is 
described in Table 1.3D. The initial release of a drug from a polymer matrix can achieve a 
therapeutic effect rapidly and then a prolonged release sustains therapeutic effect (Table 1.3D). The 
release rate from polymer is not necessarily constant for this formulation. For instance, Martin et al 
Figure 1.1 The in vivo fate of a drug. Released drug can be immediately absorbed into 
systemic circulation. Some proportion of the drug can distribute into various tissues, and 
have a pharmacologic effect. Drug can be eliminated by kidney and liver. (Shargel, Wu-
Pong et al. 2005) 
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developed a drug delivery device, which had a 13 nm nanopore membrane loaded with radio-
labeled BSA. Following implantation, this device could extend plasma levels of BSA over 45 days 
  
Table 1.3 Summary of different types of plasma level-time curves. Adapt from 
(Bajpai, Shukla et al. 2008, Gemma, Judit et al. 2012) 
19 
 
(Martin, Walczak et al. 2005). When the rate of continued release is constant and equal to the rate 
of drug elimination, the sustained release is achieved (Table 1.3 E). This type of pharmacokinetics 
was observed for a non-biodegradable drug delivery device, which consisted of a polyvinyl alcohol 
and silicone laminate. Fluocinolone acetonide exhibited sustained released from the device over 50 
weeks (Jaffe, Yang et al. 2000). Table 1.3 F shows the delayed release profile. In this system, drugs 
are protected by a polymer coating from the adverse physiological environment. Degradation of the 
polymer coating allows the release of the drug (Table 1.3 F). This delayed release can improve the 
bioavailability of therapeutics. These studies on in vivo fate of drugs released from polymer carriers 
provide important information for improving efficacy of drug therapy, and for designing 
appropriate drug delivery systems to treat different diseases. 
 
Drug delivery can be highly variable in each individual patient. Therefore, a more complex drug 
delivery system can be engineered with the capability of monitoring and adapting to changes in 
each individual physiological system. Drug efficacy in this system can be improved by ensuing that 
a drug is released only when it is needed. Diabetes, for example, is a common disease that affects 
many people (Anonymous and American Diabetes 2013). Regular injections ignore the natural 
fluctuation in glucose levels in the blood, which may lead to periods of hypoglycemia, 
hyperglycemia, coma or even death. Early drug delivery system for the treatment of diabetes relied 
on prolonged low-dose release of insulin from polymer scaffolds in a rat model for at least 100 days 
(Brown, Munoz et al. 1986). However, this system lacked a glucose-responsive component, which 
could monitor natural glucose levels. One strategy has incorporated glucose sensing, the glucose 
oxidase enzyme, within the material (Gu, Aimetti et al. 2013). This glucose-mediated insulin 
release depended on the ability of glucose oxidase catalyzing the conversion of glucose to gluconic 
acid, which was accompanied by a concomitant decrease in pH. This “smart” system was able to 
detect signal and respond to the physiological changes. In the future, “stimuli responsive” drug 
delivery systems could be designed to prolong the presence of drugs in the systemic circulation or 
at the target tissue for periods of time, be combined with a biosensor for long-term surveillance in 
the circulation, and initiate on-demand drug release upon specific biomarker recognition.  
 
1.2 Biomedical grade thermoplastic polyurethanes (TPUs) 
1.2.1 Biomedical applications of thermoplastic polyurethanes 
Thermoplastic polyurethanes (TPUs) as a special class of biomaterials have been widely used in 
medical applications due to their outstanding physical properties and biocompatibility. They have 
been used in tissue engineering scaffolds (Gorna and Gogolewski 2006), heart valves (Darren, 
Gordon et al. 2003), and pacemaker leads (Stokes and Cobian 1982). TPU is a polymer composed 
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of a number of urethane linkages (-NH-CO-O-) (Figure 1.2 A) and is formed by the reaction of 
hydroxyl and isocyanate groups.  
 
Segmented polyurethanes are characterized by three basic components: polyol, diisocyanate and 
chain extender (Figure 1.2 B). The relatively flexible component polyol, also called the soft 
segment, is an oligomeric macromonomer. It comprises a chain having a low glass transition 
temperature and is terminated by hydroxyl groups (Santerre, Woodhouse et al. 2005). Examples of 
these compounds are polytetramethylene oxide and polydimethylsiloxane. The relatively polar and 
rigid component is called the hard segment, which consists of chain extender and the diisocyanate 
components. There are some widely used diisocyanate, including 4,4’-methylene bisphenyl 
diisocyanate and methylene bis cyclohexane diisocyanate. The short chain extender has either 
hydroxyl or amine end groups, such as 1,4-butanediol and ethylene diamine (Santerre, Woodhouse 
et al. 2005).  
 
Both bio-stable and biodegradable TPUs can be designed by selection of hard and soft segments. 
The ratio of hard to soft segments and molecular weight of the chemical composition offer great 
opportunities for synthetizing different TPUs that satisfy specific property requirements (Darren, 
Gordon et al. 2003). For example, polydimethylsiloxane-based polyurethanes exhibit outstanding 
stability in water due to the stability of polydimethylsiloxane, whereas polyethylene oxide-based 
polyurethanes are sensitive to water due to the hydrophilicity of the ethylene oxide units.  
 
Because of the thermodynamic incompatibility of soft and hard segments, TPUs exhibit unique 
phase-separate morphology, in which semicrystalline or crystalline hard domains are chemically 
imbedded in amorphous soft domains (Figure 1.3). The hydrophilic or hydrophobic property of 
these domains depends on the chemical composition of the segments. This phase separated 
morphology contributes to their unique physical, elastomeric and mechanical properties (Darren, 
Gordon et al. 2003). For instance, the hard domains contribute to the mechanical strength of TPUs, 
whereas the soft domains determine the flexibility of TPUs. An increase in hard segment size can 
lead to a restriction in the mobility of polymer chains and further increase in hardness of materials. 
Despite considerable combinations of diisocyanates, chain extenders, and macrodiols, only a few 
TPUs have been used in clinical applications.  
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The use of polyurethanes in medical applications originated in 1960s, when Boretos first suggested 
using a new segmented polyurethane for molded prostheses (Boretos and Pierce 1967). Despite 
considerable effort, the biodegradation of polyurethanes appeared to be the major obstacle leading 
to the failure of long-term implanted devices in the late 1980s (Santerre, Woodhouse et al. 2005). 
The toxic degradation products may trigger biological reactions by interacting with cells and further 
cause severe damage to the body (Santerre, Woodhouse et al. 2005, Lyu and Untereker 2009). For 
long term implantation, there was a need to develop new biostable and biocompatible polyurethanes, 
which could maintain the excellent mechanical properties of implanted devices. A detailed 
summary of polyurethane-based biomedical devices is listed in Table 1.4. Today, although 
polyurethanes remain one of the most popular biomaterials, biocompatiblity problems such as 
infections, thrombosis and inflammation still hamper their application as implantable devices. To 
Figure 1.2 Structure of TPUs. (A) Urethane linkage. (B) Linear segmented polyurethane. 
The hard segments are comprised of repeat units of diisocyanate and chain extender, and 
the soft segments are linear, long-chain diols. 
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reduce these problems, effort has been made over the years to understand the biological 
mechanisms and develop strategies to make more biocompatible devices.  
 
1.2.2 Polyurethanes as drug delivery matrices 
Polyurethane matrices incorporating drugs have been investigated in different areas, such as cancer 
therapy (Yu, Ding et al. 2014), tissue regeneration (Liu, Zhang et al. 2010), treatment of infections 
(Crisante, Francolini et al. 2009), and anti-inflammatory therapies (Moura, Lima et al. 2011). 
Nowadays, polyurethane-based drug delivery systems have been developed with increasing 
functions, such as controlled drug delivery, targeting for tissue recognition, as well as pH and 
temperature responses (Wang, Gao et al. 2013). Despite only few of these experimental 
polyurethane-based drug delivery systems are used in clinical practice, these drug carriers offer 
considerable potential for drug delivery. Polyurethane-based drug delivery systems can be used to 
deliver therapeutic agents for treating diseases or used as coatings for protecting medical devices 
from adverse host responses. 
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Polyurethane-based drug delivery systems can be further classified as non-degradable and 
biodegradable systems.  
 
1.2.2.1 Non-degradable polyurethanes as drug delivery systems 
Non-degradable polyurethanes are designed for long-term applications, and the time-scale of 
degradation is negligible relative to the entire time-scale of release. The main types of non-
degradable polyurethane delivery systems include films (Simmons, Padsalgikar et al. 2008) and 
nanofibers (Kenawy, Abdel-Hay et al. 2009). The loading of drugs into non-degradable 
polyurethanes is mainly by casting and solvent evaporation.  
  
Two main systems, matrix systems and reservoir systems, are used for non-degradable 
polyurethanes. In a reservoir type system, a drug is surrounded by a polyurethane membrane, while 
in a matrix system, a drug is distributed uniformly in the polyurethane. For example, FDA-approved 
Figure 1.3 Morphological model of thermoplastic polyurethanes. Hard domains 
contain hard segments and soft domains consist of soft segments. Polyurethanes exhibit 
unique phase-separate morphology due to the thermodynamic incompatible of soft and 
hard segments 
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wound dressing SureSkin® II consists of a polyurethane film that delivers therapeutic agents for 
treating acute and chronic dermal ulcers (Aparicio Gallego, Castilla Peris et al. 2005). These 
therapeutic agents were distributed homogeneously in the polyurethane matrix. More recently, 
studies have introduced nanocomposites into polyurethane matrices to modify drug release 
(Crisante, Francolini et al. 2009).  
 
Many small molecule drugs have been incorporated into these non-degradable polyurethanes, 
including dexamethasone acetate (Simmons, Padsalgikar et al. 2008) and chlorhexidine diacetate 
(Huynh, Padois et al. 2010). It is important to note, however, that the role of non-degradable 
polyurethanes for delivery of peptides and proteins has received little attention. The main 
challenges are to retain the bioactivity of peptides and proteins during synthesis of the 
polyurethane-based peptide delivery system, and to enhance the limited diffusion of large 
macromolecules from non-swellable polyurethanes. 
 
1.2.2.2 Biodegradable polyurethanes as drug delivery systems 
Biodegradation of polyurethanes are mainly due to the cleavage of hydrolytically sensitive bonds 
present in their soft segments and oxidative degradation of urethane bonds in the hard segments 
(Cherng, Hou et al. 2013). The degradation of biodegradable polyurethanes was problematic in 
terms of their long-term in vivo biostability as biomedical devices (Santerre, Woodhouse et al. 
2005). However, the degradation property of biodegradable polyurethanes contributes to their 
application in drug delivery. Differently from non-degradable polyurethanes, biodegradable 
polyurethane-based devices and coatings are able to prolong the activity of therapeutic agents 
without the need to remove the devices after implantation. 
 
Biodegradable polyurethanes can be engineered into different physical forms as drug carriers, such 
as nanoparticles (Wang, Gao et al. 2013), microspheres (Subhaga, Ravi et al. 1995), micelles (Yu, 
Ding et al. 2014), films (Guo, Knight et al. 2009), gels (Park, Wu et al. 2011), or scaffolds 
(Hafeman, Zienkiewicz et al. 2010). Therapeutic agents can be loaded into these formulations by 
many methods, such as casting, oil-in-water emulsion/solvent evaporation, covalent link to 
polyurethane chains and adsorption. For example, an anti-cancer drug, doxorubicin, was covalently 
incorporated into biodegradable polyurethane foams due to the reaction of several isocyanate 
reactive groups with doxorubicin molecules (Sivak, Zhang et al. 2009). The release of doxorubicin 
was dependent mainly on the degradation of biodegradable polyurethane foams.  
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Biodegradable polyurethanes have been designed to deliver different therapeutics ranging from 
small molecule drugs (Guo, Knight et al. 2009) to proteins (Nelson, Baraniak et al. 2011). 
Specifically, Guo et al used polyhedral oligosilsesquioxane thermoplastic polyurethanes to 
modulate paclitaxel release. They showed that polymer degradation impacted drug release only 
when their associated rate constant was comparable to the initial diffusion rate constant (Guo, 
Knight et al. 2009). Nelson et al characterized poly(ester urethane)urea’s ability to incorporate and 
release bioactive insulin-like growth factor-1 (IGF-1) and hepatocyte growth factor (HGF). They 
found this biodegradable polyurethane could provide long-term growth factor delivery. More 
recently, the ability of biodegradable polyurethane to deliver siRNA has been explored (Nelson, 
Gupta et al. 2012). Despite the considerable investigations in designing a biodegradable 
polyurethane-based drug delivery system, few of these delivery systems have been commercialized. 
In addition, there is very little work on understanding the release of peptides from biodegradable 
polyurethane supports.  
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Table 1.4 Summary of several biomedical grade polyurethanes 
Material 
Composition 
Medical Application 
Hard segments Soft segments 
Tecoflex H12MDI/BD PTMO 
Catheters, tubing, blood pump diaphragms, wound dressings 
(Guidoin 2001) 
Pellethane MDI/BD PTMO 
Tubing, catheters, pacemaker leads (Szycher 1988), coronary 
assist devices (Taylor, Cameron et al. 2005) 
Chronoflex H12MDI/BD HMEC 
Cardiac assist devices (Zdrahala 1999), vascular grafts (Carson, 
Edwards et al. 1996) 
ElastEon MDI/BD PDMS 
pacemaker lead insulators, orthopaedics, catheters, coating of 
electrical wires and stents (Choi, Weksler et al. 2009) 
Biomer MDI/ED PTMO 
Artificial hearts, ventricular assist device, pacemaker lead 
insulators, catheters (Reed, Potter et al. 1994) 
Biospan 
MDI/ED 
Or MDI/BD 
PTMO Artificial heart (Zdrahala 1999), 
Vialon MDI/BD PTMO Catheters (Zdrahala 1999) 
Bionate MDI/BD HMEC 
Cardiac assist devices (Zdrahala 1999), neurostimulation, 
vascular, artificial heart, diagnostic devices, spinal motion 
preservation devices, orthopaedic application(Geary, 
Birkinshaw et al. 2008),  
Estane MDI/BD PTMO 
Cardiac assist devices (Zdrahala 1999), vascular grafts(Carson, 
Edwards et al. 1996) 
Corethane MDI/BD HMEC 
Replacement hip joint (Khan, Smith et al. 2005),  leads, grafts, 
stents (Guidoin 2001) 
 
MDI, 4,4’-methylene bisphenyl diisocyanate; BD, 1,4-butanediol; ED, ethylenediamine; PTMO, polytetramethylene oxide; PDMS, 
polydimethylsiloxane; H12MDI, methylene bis cyclohexane diisocyanate; HMEC, poly(1,6-hexyl 1,2-ethyl carbonate diol); 
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1.3 The interactions between biomaterials and biological systems 
1.3.1 Host responses to foreign materials 
Biocompatibility of biomaterials remains a crucial issue which can severely limit the application of 
many implantable devices. The implantation of a biomaterial into human body involves tissue 
Figure 1.4 Sequence of local responses to the implanted biomaterials. Adapted from 
(Anderson 1993). When biomaterials are exposed to body fluids, a series of events occur, 
including protein adsorption, activation of cascade systems and cell activation. Immune 
cells, such as neutrophils, macrophages, foreign body giant cells, fibroblasts, and 
mononuclear leucocytes, are recruited to the implantation site. The implanted biomaterials 
can cause acute inflammation and further initiate ongoing chronic inflammation, 
thrombotic reaction, foreign body reaction and fibrosis. 
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or organs injury, which can activate host responses, such as inflammation, foreign body reaction 
and wound healing (Anderson 1993). When biomaterials are exposed to body fluids, a series of 
events occur. Figure 1.4 shows the sequence of local responses to the implanted biomaterials. 
Proteins in the body fluid adsorb to the surface of the implanted biomaterial and change their 
conformation (Figure 1.5) (Ekdahl, Lambris et al. 2011). The adsorbed proteins activate the 
complement system and the contact activation/coagulation cascade system (Figure 1.4), which 
trigger the generation of different mediators, such as plasma proteases, growth factors, and 
cytokines (Ekdahl, Lambris et al. 2011, Franz, Rammelt et al. 2011). These mediators recruit 
immune cells to the implantation site to form an inflammatory micro-environment (Figure 1.5). 
Inflammation, a protective response to injury, can initiate the healing process (Anderson 1993). An 
implant can initiate acute inflammation rapidly. If the foreign material cannot be phagocytosed or 
removed, the acute inflammation persists to initiate ongoing chronic inflammation, thrombotic 
reaction, foreign body reaction and fibrosis (Figure 1.4) (Nilsson, Korsgren et al. 2010). Among 
these reactions, biomaterial-associated inflammation has been shown to severely limit the 
performance of many devices (Selvam, Kundu et al. 2011) and initiates many diseases, such as 
arteriosclerosis, thrombosis, and fibrosis (Ekdahl, Lambris et al. 2011). Studies have shown that 
biomaterial-related inflammation may also promote cancer metastasis (Ko, Wu et al. 2012).  
 
The inflammatory response involves various types of cells and mediators. Figure 1.4 shows the 
lifetime of cells following implantation. Neutrophils are active during the acute inflammatory phase 
and have a short lifetime (Figure 1.4). Proteases, cytokines, lysozymes, reactive radicals and other 
enzymes released by neutrophils lead to the activation of monocyte / macrophages and the removal 
of foreign materials (Anderson 1993). Activated monocytes are recruited rapidly to the site of 
implantation and differentiate into macrophages, which have a long lifetime (Figure 1.4). 
Macrophages can attach to biomaterials and lead to invasion of additional inflammatory cells. They 
can also produce regulators, such as chemokines, for tissue regeneration (Franz, Rammelt et al. 
2011). The continual presence of a foreign material leads to chronic inflammation, which is 
accompanied by the presence of macrophages and monocytes (Figure 1.4). All of these cells, 
directed by chemokines and integrins, are responsible for removing foreign materials and cleaning 
up the wound site mediators (Franz, Rammelt et al. 2011). Fibroblasts and vascular endothelial cells 
can proliferate and stimulate the formation of granulation tissue (Figure 1.4) (Anderson 1993).  
Subsequently, when macrophages fail to remove the foreign materials, they will merge to form 
foreign body giant cells, which are a consequence of the foreign body response to biomaterials 
(Figure 1.4 and 1.5) (Anderson, Rodriguez et al. 2008). Fibrosis may be the eventual healing 
response to biomaterials (Figure 1.4) (Jones 2008). These events continue until equilibrium is 
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Figure 1.5 Host responses to the implanted biomaterials. Adapted from (Ratner and 
Bryant 2004). Proteins are adsorbed immediately on the surface of biomaterials. Adsorbed 
proteins trigger the recruitment of cells to the site of implantation. Macrophages at the site 
of implantation may fuse together to form multinucleated foreign body giant cells to 
remove the implant. Foreign body reaction can lead to the formation of avascular collagen 
capsule around the implant. 
reached or the foreign material is removed. Understanding the host responses to the implanted 
biomaterials can help to develop strategies to minimize adverse reactions. 
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Surface chemical modification of biomaterials has been investigated to reduce the host response to 
biomaterials (Hsieh, Hu et al. 2014). For example, polymeric coatings are used extensively in 
modern medical devices and implants to generate more biocompatible implants (Bridges and García 
2008). Despite considerable strategies that have been developed, the adverse responses cannot be 
avoided completely. More effective therapies that minimize host responses to implanted devices 
should be developed. Implanted drug delivery systems may contribute to improve the utility of 
medical devices in vivo. 
 
1.3.2 Biomaterial responses to biological systems  
Once exposed to the physiological environment, the physical and mechanical properties of 
biomaterials may change dramatically. The responses of biomaterials to biological systems may 
vary with the site of implantation, due to different pH, O2, and temperature at different anatomical 
sites (Brown 1999).  
 
Biomaterial responses to biological systems include swelling, degradation, corrosion, and loss of 
sensitivity and function. Following implantation, attached immune cells may generate toxic 
catabolites to damage the implants (Tang and Eaton 1995). For example, some implanted devices 
used in hip prosthesis and mechanical heart valves were reported to show fatigue fracture and 
abrasive wear problems, which may result from the recruitment of leukocytes, macrophages, and 
giant cells to the devices (Teoh 2000). The process of fatigue-wear corrosion and environmental 
stress cracking are mainly due to the presence of inflammatory cells around the site of implant (Zhao, 
Agger et al. 1990). The degradation of biomaterials is governed by many biological responses, 
including oxidative degradation (Sutherland, Mahoney et al. 1993), enzymatic degradation 
(Azevedo, Gama et al. 2003), and calcification (Schoen, Harasaki et al. 1988). Furthermore, 
degradation products of biomaterials can in turn lead to toxicity, carcinogenicity, immune responses 
and infections.  
 
On the basis of understanding the interactions between biomaterials and biological systems, 
different strategies have been developed to minimize biomaterial responses to biological systems. 
These include designing new biomaterials by incorporation of new components in polymer (Santerre, 
Woodhouse et al. 2005), and modification of the surface chemistry of polymer (White, Ward et al. 
1997). However, because of the complex biological systems, problems, such as the reduced 
performance and failure of many medical devices, still hinder their applications. This emphasizes 
the importance of developing implantable drug delivery systems to minimize the responses of 
biomaterials to biological systems. 
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1.3.3 Role of complement system in biomaterial-induced inflammation 
The complement system plays an important role in the initial recognition of and defense against 
foreign materials as well as subsequent immune and inflammatory responses (Nilsson, Ekdahl et al. 
2007). Figure 1.6 shows the activation of complement system induced by implanted biomaterials, 
which involves four major steps (Hamad, Al-Hanbali et al. 2010, Ekdahl, Lambris et al. 2011). The 
first step is the recognition of non-self materials by three different pathways (Figure 1.6). The 
binding of C1q of the C1 protein to antibody or C reactive protein decorated surfaces can activate 
the classical pathway. The binding of mannan-binding lectin or ficolins to carbohydrates can trigger 
the lectin pathway. The alternative pathway can be initiated by directly binding with foreign 
materials or re-activation of the classic pathway and the lectin pathway. In the second step, these 
three major pathways converge into a common pathway by forming enzyme complexes C3 
convertases, which can cleave C3 into C3a and C3b (Figure 1.6). The third step is the generation of 
C5 convertases, which result in the cleavage of C5 into C5a and C5b (Figure 1.6). The fragment 
C5b may induce formation of the membrane attack complex (MAC or sC5b-9). In the fourth step, 
mediators, such as C3a, C5a, and sC5b-9, activate and recruit inflammatory cells to the 
implantation site (Figure 1.6). The activated inflammatory cells can further activate many adverse 
reactions, including inflammation, cell lysis and thrombosis (Figure 1.6).  
 
The activation of the complement system may be governed by the adsorbed protein layer around 
implanted biomaterials. Within this layer, C3 has been shown to adsorb directly to the biomaterial 
surface and change conformation to generate alternative pathway convertase (Andersson, Ekdahl et 
al. 2002). Adsorbed human immunoglobulin G (IgG) on silicone surface has been shown to activate 
complement via the classic pathway (Tengvall, Askendal et al. 2001). Studies have shown that 
deposition of complement C3b on cuprophane membrane was mediated by the classic pathway 
(Lhotta, Würzner et al. 1998). In addition, biomaterial surface properties may also affect the 
activation of complement. Poly(vinyl alcohol)-immobilized surfaces can initiate complement 
through the alternative pathway (Arima, Kawagoe et al. 2009). Studies have shown that the amount 
of C3b adsorbed on the surface of self-assembled monolayer of 11-amino-1-undecanethiol was less 
than the surface of self-assembled monolayer of 11-mercaptoundecanol (Toda, Kitazawa et al. 
2008). These examples demonstrate the importance of the complement system in mediating 
biomaterial-induced inflammation. Inhibiting complement activation may be an effective strategy to 
minimize this inflammatory response. 
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1.3.4 Biomaterial-induced C5a receptor (C5aR) signaling 
The anaphylatoxin C5a, generated at the implant site, contributes to the initiation of inflammatory 
response by interacting with immune cells (Franz, Rammelt et al. 2011). It is a 74 amino acid 
protein fragment, and is reported to interact with two receptors, the G-protein coupled C5a receptor 
(C5aR, CD88) and the non-G-protein coupled C5a receptor-like 2 receptor (C5L2) (Kohl 2006, 
Proctor, Woodruff  et al. 2006). Studies have shown that C5aR signalling played an important role 
in biomaterial-induced complement activation (Kourtzelis, Rafail et al. 2013). C5a interacts with 
the C5a receptor on polymorphonuclear leukocytes, monocytes and mast cells, which can induce 
classical signaling and cause the release of pro-inflammatory cytokines and chemokines, such as 
TNF-α, IL-1 and IL-8 (Nilsson, Ekdahl et al. 2007). This interaction leads to mast cell 
degranulation, activating granulocytes and monocytes and inducing granulocyte reactive oxygen 
species release (Sarma and Ward 2011).   
 
Inhibition of C5a and C5aR binding improves survival and attenuates many disease models 
including rheumatoid arthritis, inflammatory bowel disease, ischaemia-reperfusion injury, sepsis, 
Huntington’s disease and Alzheimer’s disease (Woodruff, Proctor et al. 2006).  Recent studies have 
shown that inhibition of C5aR signalling could impair tumor growth (Markiewski, DeAngelis et al. 
2008). Several strategies have been developed to inhibit the interaction of C5a and C5aR to reduce 
the risk of these diseases, such as using peptidic and non-peptidic C5a receptor antagonists (Monk, 
Scola et al. 2007).  
 
The most advanced C5a inhibitor drug candidate is the small molecule cyclic peptide PMX53 (AcF-
[OP(D-Cha)WR]). It was first reported in 1999 (Finch, Wong et al. 1999) and has been shown to 
inhibit the binding of C5a to C5aR, but not to C5L2 (Otto, Hawlisch et al. 2004). PMX53 has 
shown safety, tolerance and clinical effect (Kohl 2006). It has been investigated in several disease 
models such as inflammatory bowel disease (Woodruff, Arumugam et al. 2003), incisional pain 
(Jang, Liang et al. 2011), tumor growth (Markiewski, DeAngelis et al. 2008), ischaemia-reperfusion 
injury (Arumugam, Shiels et al. 2003), and neurological dysfunction (Li, Fan et al. 2014). However, 
PMX53 has poor bioavailability after oral administration and fast elimination in vivo (Morgan, 
Bulmer et al. 2008). A new method of administration that increases PMX53 pharmacologic effects 
is required.  
 
A series of other cyclic or non-cyclic peptide inhibitors has been developed, including AcF-[OP(D-
Cha)WCit] (PMX201), hydrocinnamate-[OP(D-Cha)WR] (PMX205) (Proctor, Woodruff et al. 
2006), and Hoo-Phe-Orn-Pro-hle-Pff-Phe-NH2 (JPE1375) (Schnatbaum, Locardi et al. 2006).  
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Figure 1.6 Complement activation induced by implantation of biomaterials. Molecules of 
the complement cascade system may recognise the implanted biomaterials and trigger the 
complement system though different pathways. These three major pathways converge into a 
common pathway by forming enzyme complexes C3 convertases, which cleave C3 into C3a 
and C5 convertase. The generated C5 convertases cleave C5 into C5a and C5b. The fragment 
C5b may induce formation of the membrane attack complex (MAC or sC5b-9). The mediators, 
such as C3a, C5a, and sC5b-9, may activate and recruit inflammatory cells to the implantation 
site and active many adverse reactions. 
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Inhibition of C5a receptor protects all other complement pathways, which may be important for 
long-term and repeated attenuation of the complement-mediated inflammatory response. Therefore, 
delivery of C5aR antagonists, such as PMX53, using polymeric matrices may be an effective 
strategy to minimize the activation of biomaterial-associated complement system, which may 
further reduce inflammatory response. 
 
In summary, the role of both non-degradable and degradable polyurethanes as matrices for peptide 
delivery has received little attention. However, these polyurethane-based drug delivery systems 
offer the valuable potential for clinic therapy. In this project, we focused on developing TPU-based 
peptide delivery systems. These systems are designed to minimize biomaterial-induced 
complement-mediated inflammatory response by inhibiting C5aR signalling and may be used to 
deliver therapeutic peptides or combined with existing medical devices. Although these TPU-based 
peptide delivery systems developed in this project are still at an investigational stage, they provide 
important information for peptide delivery in the clinic.  
 
1.4 Aims 
This project aimed to investigate the capability of thermoplastic polyurethanes to deliver 
therapeutic peptides, such as C5aR antagonists, understand the release kinetics, and 
pharmacological responses to released peptides. Specifically, 
 
Aim 1 Comparing the effect of supercritical carbon dioxide treatment and solvent casting on 
physical properties of TPU films; 
Aim 2 Investigating the loading and release of model drugs from TPUs and mathematical modeling 
of model drug release;  
Aim 3 Investigating the in vitro release of C5aR antagonists from TPU films; 
Aim 4 Investigating the in vivo pharmacokinetics and pharmacodynamics of PMX53 from TPU 
films. 
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Chapter 2  
Materials and methods 
 
 
 
 
 
 
 
 
 
 
 
2.1 General chemicals and materials 
All chemicals used in this project were of analytical grade unless otherwise specified. All solutions 
were prepared using MilliQ H2O (18.2 MΩ.cm at 25oC). Phosphate buffered saline (PBS) pH=7.4 
was prepared following the standard operating procedure: 137 mM NaCl; 2.67 mM KCl; 8.1 mM 
Na2HPO4; 0.74 mM KH2PO4.  HCl (10.2 M) or NaOH (10 M) was used to adjust pH to 7.4. 
Sterilized solutions, glassware, tubes, surgery equipment were prepared by autoclaving at 121oC for 
20 min. Heparin sodium solution was prepared for preventing the formation of blood clots by 
dissolving 20 U.S.P. units in 20 µl PBS for 1 ml blood. The general chemicals used in this thesis are 
listed in Table 2.1. 
 
The thermoplastic polyurethanes (TPUs) ElastEon (E5325), Pellethane (2363-80A, 2363-90A) and 
Tecoflex (72A, 80A) were kindly supplied by AorTech Biomaterials Pty Ltd. Their compositions 
are described in Figure 3.6A (Chapter 3). Peptides were supplied by the School of Biomedical 
Sciences, the University of Queensland, except for Xen2174 provided by Institute for Molecular 
Bioscience, the University of Queensland. 
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Table 2.1 Chemicals used in this thesis 
Chemical Name 
Chemical Formula or 
Abbreviation / Synonyms 
Manufacturer 
Rhodamine B C28H31ClN2O3 Sigma Aldrich 
7-hydroxycoumarin C9H6O3 Sigma Aldrich 
Fluorescein C20H12O5 Sigma Aldrich 
Dimethylacetamide CH3C(O)N(CH3)2 
Liquid chromatography grade 
Merck Millipore 
Methanol CH3OH 
Liquid chromatography grade 
Merck Millipore 
Dichloromethane CH2Cl2 
Liquid chromatography grade 
Merck Millipore 
Tetrahydrofuran (CH2)4O 
Liquid chromatography grade 
Merck Millipore 
Acetonitrile CH3CN 
Liquid chromatography grade 
Merck Millipore 
Formic Acid HCOOH Ajax Finechem 
Roswell Park Memorial 
Institute 1640 medium (1X) 
RPMI 1640 Gibco by lift technologies 
Dulbecco's Modified Eagle 
Medium (1X) 
DMEM Gibco by lift technologies 
Fetal bovine serum FBS Gibco by lift technologies 
Penicillin-Streptomycin - Gibco by lift technologies 
0.25% Trypsin- 
ethylenediaminetetra acetic 
acid (1X) 
Trypsin-EDTA 
 
Gibco by lift technologies 
Ethanol C2H6O Merck Millipore 
Dimethylsulfoxide DMSO Sigma Aldrich 
Hydrochloric acid (10.2 M) HCl Ajax Finechem 
Sodium hydroxide (10 M) NaOH Lab-Scan 
Paracetamol - Sigma Aldrich 
Heparin sodium salt from 
porcine intestinal mucosa 
- Sigma Aldrich 
Betadine - MCP operations 
Poly-L-lysine solution - Sigma Aldrich 
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2.2 Preparation of thermoplastic polyurethane (TPU) films 
Each of the TPUs was initially dried at 60°C for 24 h prior to use. For physical property study and 
release after the loading of three model drugs, TPUs were then dissolved in dimethylacetamide 
(DMAc) at a concentration of 10% (wt:wt). The solution was poured into a glass dish and dried at 
60 - 75°C for 5 h in a stream of nitrogen gas. Films were then annealed under vacuum at 85°C for 5 
h and left to age at room temperature prior to use. Model drugs were dissolved in DMAc and mixed 
with the TPUs at varying concentrations and then poured into dishes as described above. The 
resulting films were approximately 0.1 mm in thickness measured by caliper. When model drugs 
were co-cast with pore former PEG 4000 or PEG 10000 (20% wt/TPU wt), they were dissolved in 
methanol and mixed with TPUs. 
 
For the efflux of peptides, TPUs were dissolved in dichloromethane or tetrahydrofuran at a 
concentration of 5% (wt/v). When peptides were co-solvent cast, they were dissolved in methanol 
and mixed with the TPUs. The solution was poured into a Teflon dish and dried at room 
temperature under vacuum. For in vivo study, TPUs were dissolved in dichloromethane at a 
concentration of 5% (wt/v). The TPU solution with or without peptides (200 µg) was added into an 
18-well Teflon plate, and dried at room temperature under vacuum. 
 
2.3 ScCO2 treatment 
TPU films (1 cm x 1 cm) were arranged in a stainless steel reaction vessel using a wire net to secure 
them in place and prevent contact during impregnation. Figure 2.1 shows the schematic of scCO2 
apparatus. Model drug in methanol was introduced into the bottom of the vessel. Liquid CO2 was 
then fed from the top of the vessel under high-pressure (~ 6 MPa). The reaction pressure and 
temperature in vessel were increased to 15 MPa and 40°C, respectively, and maintained for 4 h. 
After the reaction, the vessel was cooled to room temperature and the CO2 was then vented. 
 
2.4 Mechanical property analysis 
The tensile properties of the TPUs were examined at room temperature using an Instron model 5543 
universal testing machine equipped with a 50 N load cell. Dumbbells were cut from cast TPU sheets 
using an ASTM D-638-M-3 die, and the applied crosshead speed was 50 mm/min. 
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2.5 Atomic force microscopy (AFM) 
AFM measurement was co-performed by Elena Taran and the author. Surface morphology of the 
TPU following scCO2 treatment was imaged using a MFP-3D (Asylum Research) atomic force 
microscope (AFM). All images were obtained by employing the tapping mode. The topography 
images were measured using HA_NC (Etalon) cantilevers with a nominal resonant frequency of 
165 kHz. Near surface mechanical properties were determined by measuring a 32 × 32 force curve 
array over a 1 µm × 1 µm area at 50 nN applied force and 1 mm/s tip velocity. All force curves 
were measured in PBS at the designated time points using a HA_NC tip with a nominal spring 
constant of approximately 5 N/m. Prior to use the cantilevers had been calibrated against a glass 
slide, using the thermal vibration method embedded in the AFM processing software. The Young’s 
modulus (E) was computed from force curves using a Hertz model. The force curve data were 
analysed using IGOR software.  
 
2.6 Differential scanning calorimetry  
In order to investigate subtle changes in TPU phase morphology, thermal analysis was performed 
using a Mettler Toledo DSC 1 Star calorimeter. The sample (approximately 5 mg) was sealed in the 
Figure 2.1 Schematic of scCO2 apparatus. Model drugs were added into the bottom of the 
reaction vessel. Liquid CO2 was fed from the top of the vessel. The pressure and temperature 
were increased to 15 MPa and 40oC by pump and temperature controller, respectively. After 
reaction, CO2 was vented. 
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DSC aluminium pan. The temperature was increased from 25°C to 200°C, then cooled to 25°C at 
the same rate of 10°C/min in N2 atmosphere. 
 
2.7 Dynamic mechanical thermal analysis 
The soft microphase Tg transition of the TPUs was measured using a Rheometric Scientific dynamic 
mechanical thermal analyser (DMTA IV) equipped with a tensile head and reducing force option. 
Samples were examined at a frequency of 2 Hz using a heating rate 2°C/min from -100°C to 50°C. 
 
2.8 Model drug uptake and release studies 
The drug concentration in each of the TPUs was determined by dissolving a known weight of film 
and then quantifying fluorescence using a BMG LABTECH microplate reader or Luminescence 
Spectrometer 50 B with filters set at excitation 555 nm, emission 570 nm for rhodamine B, 
excitation 325 nm, emission 385 nm for 7-hydroxycoumarin, and excitation 485 nm, emission 520 
nm for fluorescein. For drug release studies, solvent cast films or films treated with scCO2 were 
immersed in 10 ml phosphate buffered saline (PBS) for up to 5 days in the dark with constant 
mixing on a rotating wheel at room temperature. Samples (100 µl) were withdrawn at each time 
point and drug concentration was measured against a standard curve using a BMG LABTECH 
microplate reader. Each experiment was conducted in triplicate. Data are presented as mean ± 
S.E.M. 
 
2.9 Fluorescence imaging of TPU films 
Solvent cast and scCO2 drug-loaded films were sectioned vertically into thin strips for viewing 
using an OLYMPUS IX51 fluorescence microscope. Images were captured electronically and 
fluorescence intensity was quantified using Photoshop software. 
 
2.10 Measurement of water uptake 
Water uptake of TPU films was measured using moisture analyser MF-50. Films around 200 µg 
were immersed in 60 ml MilliQ H2O and then incubated at 37
oC for 24 h. Surface of films was 
dried by filter papers. Samples were dried by immediately increasing temperature to 105oC and 
maintaining for 30 min. The mass change was monitored. Water uptake was calculated by the 
following equation: 
 
𝑤𝑎𝑡𝑒𝑟 𝑢𝑝 (%) =  
𝑚𝑤𝑒𝑡 − 𝑚𝑑𝑟𝑖𝑒𝑑
𝑚𝑤𝑒𝑡
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2.11 Quantification of peptides using liquid chromatography-mass spectrometry (LC-
MS) 
Peptides were analysed by LC-MS using an Agilent API 3200 LC/MS/MS. Peptides (5 µl), except 
SFTI-1, were injected onto an Agilent C18 column 2.1 x 150 mm and eluted using the water-
acetonitrile gradient:  5% acetonitrile containing 0.1% formic acid linear increase to 100% from 0 to 
0.2 min, hold at 100% acetonitrile/0.1% formic acid from 0.2 to 5 min, and linear decrease to 5% 
acetonitrile/0.1% formic acid from 5.0 to 5.1 min, hold at 5% acetonitrile/0.1% formic acid for 20 
min, at the flow rate of 150 µl/min. For SFTI-1, samples (5 µl) were eluted using the water-
acetonitrile gradient:  5% acetonitrile containing 0.1% formic acid linear increase to 50% from 0 to 
0.2 min, hold at 50% acetonitrile/0.1% formic acid from 0.2 to 5 min, and linear decrease to 5% 
acetonitrile/0.1% formic acid from 5.0 to 5.1 min, hold at 5% acetonitrile/0.1% formic acid for 10 
min, at the flow rate of 150 µl/min.  
 
The column temperature was 40oC, and the sample plate temperature was 4oC. Parameters for LC-
MS condition of each peptide were summarized in Table 2.3. The optimal mass 70.1 Da for PMX53, 
197 Da for JPE1375, 70.1 Da for PMX201, 70.1 Da for PMX205, 84.1 Da for Xen2174, and 70.2 
Da for SFT-1 were used to analyse results. The concentration of each peptide was measured against 
each standard curve. Peak area was analysed by Analyst MultiQuant software. Each experiment was 
conducted in triplicate. Data are presented as mean ± S.E.M. For mass spectrometry tuning, 
peptides were prepared in methanol-H2O (1:1, v/v) containing 0.1% formic acid.  
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Table 2.2 Parameters for mass spectrometry tuning 
Peptide 
Name 
Mw 
Q1 
(Da) 
Q3 
(Da) 
OPIM 
(Da) 
CG ISV Temp ISG 1 ISG 2 DP EP CEP CE 
CX
P 
LC-
MS RT 
PMX53 895.3 896.3 
70.1 
70.1 10 5500 0 15 0 156 10.5 34 129 4 7.11 120.1 
159.2 
JPE1375 954.5 955.5 
197.3 
197.3 20 5500 500 40 40 91 10.5 36 75 6 7.11 225.1 
70.1 
PMX201 896.3 897.3 
70.1 
70.1 10 5500 0 15 0 106 10.5 38 127 4 7.44 159.2 
223.2 
PMX205 838.5 839.5 
70.1 
70.1 10 5500 0 15 0 116 10.5 36 127 4 7.27 159.2 
223.3 
Xen2714 1403 702.9 
84.1 
84.1 10 5500 0 15 0 76 8.5 26 105 4 6.68 72.0 
110.2 
SFT-1 
1512.
8 
757.6 
70.2 
70.2 20 5500 500 40 40 76 9 32 129 4 8.55 84.1 
86.1 
 
Mw: molecular weight, OPIM: optimal product ion mass, CG: curtain gas, ISV: ion spray voltage, Temp: temperature, ISG: ion source gas, DP: 
declustering potential, EP: entrance potential, CEP: collision cell entrance potential, CE: collision energy, CXP: collision cell exit potential, RT: 
retention time. 
 
  
 
49 
 
 
2.12 Stability of peptides at elevated temperature and organic solvents 
To measure the stability of peptides at elevated temperature, C5aR antagonists were incubated with 
or without Tecoflex 80A in dimethylacetamide (DMAc) solutions for 5 h at 60°C and 5 h at 80°C, 
which are the conventional conditions to dry and anneal TPUs. Tecoflex 80A were precipitated by 
adding MilliQ H2O (volume ratio of 1:1). Samples were centrifuged at 13,000 g for 20 min. 
Supernatants (50 µl) were withdrawn and measured by LC-MS using the method described above. 
The stability of peptides in organic solvents were investigated by incubating C5aR antagonists in 
different organic solvents, methanol, dichloromethane, tetrahydrofuran (THF) and DMAc 
respectively, for 4 h and measured by LC-MS. These organic solvents are widely used to dissolve 
many polymers. 
 
2.13 In vitro release of C5aR antagonists from TPU films 
C5aR antagonist-loaded films were cut into 1x1 cm2, and immersed in 4.5 ml different media (Milli 
Q water, PBS, 10% FBS in RPMI, respectively) with constant mixing on a rotating wheel at 37oC. 
Samples (0.4 ml) were withdrawn at each time point and freeze-dried. For the efflux in 10% FBS-
RPMI, acetonitrile containing 1% formic acid (1.2 ml) were added into each time point samples to 
precipitate proteins, and samples were centrifuged at 13,000 g for 10 min prior to freeze-drying 
process. All freeze-dried samples were re-dissolved in 50 µl methanol and centrifuged at 13,000 g 
for 1 min to separate undissolved salts. Supernatant (5 µl) was injected into LC-MS using the 
method described above. Peptide concentration was measured against each standard curve prepared 
in different media using the same method. Each experiment was conducted in triplicate. Data are 
presented as mean ± S.E.M. 
 
2.14 FITC-labeled FBS 
Proteins in fetal bovine serum (FBS) were labeled by fluorescein isothiocyanate (FITC) following 
the manufacturer’s protocol. Briefly, FBS was diluted in sodium carbonate (0.1 M, pH=9). FITC 
dye solution (10 mg/ml in DMSO) was added drop wise into FBS and incubated at room 
temperature in dark for 1 h. Unbound FITC was separated by PD-10 Desalting column. The elute of 
FITC-labeled FBS was collected and examined by a NanoDrop®
 
ND-1000 using ND1000 software 
V3.1.0 (NanoDrop Technologies, Wilmington, Delaware, USA). Films were immersed in FITC-
labeled FBS for 1 h at room temperature in dark. For control samples, FITC solution without FBS 
was separated by PD-10 Desalting column, and the same time point eluate as that of FITC-labeled 
FBS was collected.  T80A films were incubated in the eluate solution under the same condition. 
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After incubation, T80A films were then sectioned vertically into thin strips for viewing using an 
OLYMPUS IX51 fluorescence microscope.  
 
2. 15 Culture of cell lines 
2.15.1 Cell culture and differentiation of U937 cells 
U937 cells (ATCC, Human leukemic monocyte lymphoma cell line) were grown in RPMI 1640 
medium supplemented with 10% FBS, 2 mM glutamine, and penicillin (50 U/ml)/streptomycin (50 
µg/ml) at 37oC with 5% CO2. U937 cells were grown in Nunc Nunclon
TM delta surface treated 75 
cm2 flasks (Thermo Fisher Scientific, Roskilde, Denmark), and were subcultured every second day 
by replacement of medium. For induction of C5aR, U937 cells were differentiated with 100 mM 
N6-2’-O-dibutyryladenosine 3’:5’-cyclic monophosphate for 48 h. 
 
2.15.2 Cell culture of B16-F10 and Raw 264.7 cells 
B16-F10 (ATCC, mouse melanoma) and Raw 264.7 cells (ATCC, mouse leukemic monocyte 
macrophage cell line) were cultured in DMEM medium containing 10% FBS, 2 mM glutamine, and 
penicillin (50 U/ml)/streptomycin (50 µg/ml) at 37oC with 5% CO2. B16-F10 melanoma cells were 
grown in Nunc NunclonTM delta surface treated 75 cm2 flasks, and were subcultured every 2 or 3 
days by washing once with PBS and then dissociated from the flask by adding 1ml trypsin-0.25% 
ethylenediaminetetraacetic acid (tyrpsin-EDTA) for 10 min at 37oC with 5% CO2. Cells were 
resuspended in fresh medium. A small portion of cells were maintained by adding fresh medium. 
Raw 264.7 cells were grown on Nunc NunclonTM delta surface treated 100 mm dish and subcultured 
every 2 or 3 days by scraping cells from dish with a cell scraper. A small portion of cells suspension 
was added into fresh medium for subculture. 
 
2.16 In vitro bioactivity: [Ca2+]i measurements in U937 cells 
The 96-well Costar plate was coated with Poly-L-lysine (0.01% w/v) for 10 min and washed with 
PBS once. U937 cells were differentiated by treating with N6-2’-O-dibutyryladenosine 3’:5’-cyclic 
monophosphate (100 mM) for 48 h. Differentiated U937 cells were centrifuged at 400 g for 5 min 
to remove the growth medium and resuspended in Fluo-4 NW dye solution (Invitrogen). Cells 
(125,000 cells per well) in Fluo-4-NW dye solution were plated in the 96-well plate, incubated 30 
min at 37oC, and then centrifuged at 400 g for 3 min. C5aR antagonists (25 µl), released peptides, 
and PBS were added into each well respectively. After 10 min incubation, C5a (10 nM) was added 
into each well. The changes in the intracellular Ca2+ concentration were measured at an excitation 
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wavelength of 495 nm and an emission wavelength of 516 nm using a fluorescence microplate 
reader. 
 
2.17 In vivo pharmacokinetics 
2.17.1 Surgical procedures 
All in vivo experiments were performed in accordance with approval from the University of 
Queensland Animal Ethics Committee, Australia. Male C57BL/6 mice of 6 to 8 weeks old were 
housed in cages and given free access to standard food and water, and acclimated two days prior to 
surgery. The animals were anesthetized with 80% isoflurane in 20% oxygen and then maintained 
using 60% isoflurane in 40% oxygen. Mice were then removed hair on the abdomen, and wiped 
with 70% ethanol twice and betadine once. A small incision was made in the abdomen. TPU films 
containing 200 µg of peptide PMX53 were implanted. The incision was sutured using 6.0 USP silk 
sutures (Assut sutures of Switzerland). Post-operation pain was controlled by injecting 
subcutaneously with 50 µl paracetamol (10 mg/ml) after the surgery. Animals were allowed to 
recover from anaesthesia. 
 
2.17.2 Blood harvesting and processing 
Blood samples were collected at predetermined time points (0.5 h, 1.5 h, 2.5 h, 4 h, 8 h, 1 d, 3 d, 6 d 
and 9 d) into heparinized tubes by cardiac puncture. Blood samples were immediately centrifuged at 
13,000 g for 1 min at room temperature. Plasma samples were collected. JPE1375 was added into 
each sample as internal standard before adding acetonitrile with 1% formic acid (volume ratio of 
3:1) to precipitate proteins. Samples were centrifuged at 13,000 g for 10 min. Supernatant was 
withdrawn and freeze-dried. All samples were re-dissolved in 50 µl methanol and centrifuged at 
13,000 g for 1 min to separate undissolved salts. Supernatant (5 µl) was measured by LC-MS. The 
standard curve were prepared in serum and processed using the same method. 
 
2.17.3 Tissue harvesting and processing 
Liver tissue (around 50 mg) from mice implanted with PMX53-loaded TPU films was collected at 
each time point in 0.5 ml MilliQ H2O, PMX205 was added into each sample as internal standard 
prior to sonication. Acetonitrile with 1% formic acid was added into each sample to precipitate 
proteins prior to centrifugation at 13,000 g for 10 min (volume ratio of 3:1). Supernatant was 
collected and freeze-dried. All samples were re-dissolved in 100 µl methanol and centrifuged at 
13,000 g for 1 min. Supernatant (5 µl) was measured by LC-MS. For preparation of standard curve, 
liver tissue from untreated mice was collected. PMX53 standards and internal standard PMX205 
 
52 
 
were added into liver solution prior to sonication. The standard curve samples were prepared 
following the same protocol. 
 
2.17.4 In vivo release of PMX53 from TPU films 
Implanted films were collected after in vivo efflux and washed in MilliQ H2O. Films were dried 
using filter paper prior to immersing in 1 ml ethanol for 24 h. Ethanol was used to swell TPU films 
and dissolve unreleased PMX53. The amount of PMX53 remaining in the films was measured using 
LC-MS. The amount of PMX53 released from films was calculated by: the total amount of PMX53 
in TPU films minus the amount remaining in films after in vivo efflux. The total amount of PMX53 
in TPU films was determined by casting PMX53-loaded (200 µg) films and immersing in 1 ml 
ethanol.  
 
2.18 In vivo pharmacodynamics 
2.18.1 Expression of C5aR on B16-F10 cells and Raw 264.7 cells 
The expression of C5aR on B16-F10 melanoma cells and Raw 264.7 cells (positive control) was 
measured by real-time PCR. RNA was extracted from cells using RNeasy Mini kit according to the 
manufacturer’s protocol and stored at -20oC for synthesizing cDNA. Template cDNA was prepared 
by following the manufacturer’s protocol. Each sample contained 1 µl cDNA template, 2.5 µl 2.5 
µM forward primers, 2.5 µl 2.5 µM reverse primers, 12.5 µl 2 x SYBR Green supermix, and MilliQ 
H2O to finial total volume 25 µl. The product length was 131 bp. β-actin was used as an internal 
control and normalisation. Real time PCR conditions and primer information are detailed in Table 
2.4.  
 
Table 2.3 Real time PCR conditions and primer information 
Primer Sequence Real time PCR 
conditions 
C5aR Forward  5’-GGGATGTTGCAGCCCTTATCA-3’ 95oC for 1.5 min, 
followed by 40 cycles of 
95 oC for 15 sec, 60oC for 
15 sec, and 72oC for 15 
sec 
C5aR Reverse  5’-CGCCAGATTCAGAAACCAGATG-3’ 
β-actin Forward  5’-TCACCCACACTGTGCCCATCTACGA-3’ 
β-actin Reverse 5’-CAGCGGAACCGCTCATTGCCAATGG-3’ 
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The relative expression of C5aR was calculated from the following equation: 
 
𝑋
𝑋𝑟𝑒𝑓
= 2𝐶𝑡𝑟𝑒𝑓−𝐶𝑡 
 
where 𝑋/𝑋𝑟𝑒𝑓 is number of template molecules in relation to a reference gene (β-actin). 
 
2.18.2 Effect of PMX53 released from TPU films on the B16-F10 melanoma tumor growth  
To investigate whether PMX53 released from TPU films retained their bioactivity, we evaluated the 
effect of released PMX53 on B16-F10 melanoma tumor growth. B16-F10 (ATCC, mouse 
melanoma) were cultured in vitro in DMEM medium containing 10% FBS, 2 mM glutamine, and 
penicillin (50 U/ml)/streptomycin (50 µg/ml) at 37oC with 5% CO2. When the cells approached to 
about 80% - 90% confluence, cells were then trypsinised and resuspended in PBS. Each wild-type 
C57BL/6 mouse was injected subcutaneously with 200,000 B16-F10 melanoma cells in the rear 
right flank in a volume of 100 µl using a 25 gauge needle. Mice body weight was monitored every 
day after injection of B16-F10 cells. On the fourth day after cells injection, mice were anaesthetised 
and implanted with blank 50% Tecoflex 80A-50% ElastEon 5325 films and films containing 200 
µg of PMX53. Mice were allowed to recover from surgery. At day 6 after cells injection, mice were 
anesthetized and their tumor size was measured with caliper every day until the tumor size reached 
about 800 mm3, at which time mice were sacrificed. The tumor volume was calculated with the 
following formula: 
 
𝑉𝑜𝑙𝑢𝑚𝑒 = (𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ × 𝑑𝑒𝑝𝑡ℎ)/2 
 
where the depth of tumor was estimated based on the smaller (width) measurement, 
 
𝑉𝑜𝑙𝑢𝑚𝑒 =
𝑙𝑒𝑛𝑔𝑡ℎ × 𝑤𝑖𝑑𝑡ℎ2
2
 
 
At the time of mice were sacrificed, tumor was collected and weighted. 
 
2.19 Data analysis and statistics 
Data are expressed as mean ± S.E.M. Prism 6.0 (GraphPad) software was used for statistical 
analysis. All standard curves were analysed by linear regression (Prism 6.0, GraphPad), and the 
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goodness of fit was determined by using coefficient of determination (R2). All mathematic 
modeling data were analysed by nonlinear least-squares regression (Prism 6.0, GraphPad) using 
several different published models that describe drug efflux from a solid matrix or drug plasma 
levels. Significance was assumed at P<0.05. The statistical tests used are indicated in the text 
accompanying the results. These tests included:  
 
- Student’s t-test.  
- One-way and two-way ANOVA. 
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Chapter 3  
 
Effect of supercritical carbon dioxide on the 
loading and release of model drugs from 
polyurethane films: comparison with solvent 
casting 
 
 
 
 
 
 
 
 
 
Most of this chapter, including the major findings is published in Macromolecular Chemistry and 
Physics: 
Zhang, J., D. J. Martin, et al. (2014). "Effect of Supercritical Carbon Dioxide on the Loading and 
Release of Model Drugs from Polyurethane Films: Comparison with Solvent Casting." 
Macromolecular Chemistry and Physics 215(1): 54-64. 
  
 
56 
 
3.1 Introduction 
 
Thermoplastic polyurethanes (TPUs), both biodegradable and non-biodegradable, have been studied 
as potential drug delivery matrices with some films showing excellent sustained drug release 
profiles over time (Guo, Knight et al. 2009, Cherng, Hou et al. 2013, Lluch, Lligadas et al. 2013).  
Drug-impregnated films transplanted into animals have demonstrated significant anticancer and 
antibiotic activity (Kang, Lee et al. 2010, Li, Brown et al. 2010). Moreover, Basak et al. showed 
that coating of medical devices with polyurethane containing antibiotics may be a novel approach 
for minimizing infection following surgical implantation (Basak, Adhikari et al. 2009). This 
concept can be extended to include specific components of medical devices that are fabricated from 
TPUs, such as electrical lead sheaths or stent materials. In addition, drugs that prevent infection, 
minimize inflammation or enhance the healing process could be utilized, both separately and 
together. However, there are a number of potential drawbacks with these approaches. The different 
drugs need to be loaded into the TPU without compromising the medical device performance or the 
mechanical properties of the polymeric components. Secondly, localized release needs to match the 
onset and duration of the pathology requiring treatment. The timing for this may be as short as 
several hours or as long as several weeks following surgery. 
 
There are several different approaches under investigation for loading drugs into a polymeric 
material. For intraocular lens material used to treat cataracts, antibiotic and anti-inflammatory 
agents have been impregnated using techniques such as soaking the lenses in a drug solution or the 
employment of supercritical fluid technology (Gonzalez-Chomon, Concheiro et al. 2011). This 
latter method is attractive because it avoids organic solvents, can better dissolve many drugs than 
aqueous solutions, and can penetrate into most materials, including TPUs (Beckman 2004). For 
pharmaceutical applications, supercritical carbon dioxide (scCO2) has been widely used.  It is 
inexpensive, stable and does not generate residues in the end-product, which could compromise 
their medical applications (Subramaniam, Rajewski et al. 1997). scCO2 is an excellent solvent for 
many polar and non-polar small molecules, but not for most high molecular weight polymers 
(Cooper 2000). However, the solubility of scCO2 in polymeric material can still be high leading to a 
CO2-swollen material (Thurecht, Hill et al. 2005).  This makes the method worthy of exploration for 
loading small molecule drugs into TPUs.  
 
TPUs comprise a mixture of alternating hard and soft segments that are thermodynamically 
incompatible (Gogolewski 1989) and segregate into different micro-domains following casting or 
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melt processing (Hernandez, Weksler et al. 2007). Because of their extensive use in medical devices, 
TPUs are increasingly under investigation for drug delivery. To date, most studies have prepared 
material either by casting the therapeutic agent along with the polymer or simply immersing the 
polymer in drug solution (Halliday, Moulton et al. 2012). There are very few studies that have 
compared drug uptake, stability and release from TPUs following scCO2 impregnation. Moreover, it 
is not well understood how this treatment might influence the micromorphology, and hence 
mechanical properties, of the polymeric material. 
 
In the present study, we have investigated the disposition of 3 model drugs in a series of TPUs with 
significantly different hard and soft segment chemistries.  We have compared both the uptake and 
release profiles of these drugs following scCO2 impregnation with that following solvent casting. In 
addition, we have quantified the effects of scCO2 on the mechanical properties of TPUs used in 
medical devices. ElastEon in this chapter is ElastEon 5325. Tecoflex and Pellethane represent 
Tecoflex 80A and Pellethane 80A, respectively. 
 
3.2 Result 
 
3.2.1 TPU characteristics and mechanical properties 
We initially examined the effect of scCO2 treatment on the mechanical properties and microphase 
morphology of the ElastEon TPU, which consists of a combination of 4,4-methylenediphenyl and 
1,4-butanediol in the hard segment and a mixture macrodiol of α,ω-hydroxy-terminated 
polydimethylsiloxane and polyhexamethylene oxide in the soft segment (Choi, Weksler et al. 2009). 
ElastEon is widely used in biomedical applications (Martin, Warren et al. 2000). Figure 3.1A shows 
no significant change in the tensile curves of control and scCO2 treated ElastEon up to a strain of 
600%. Moreover, there were no statistical differences in tensile stress or strain at break, stiffness as 
measured by Young’s modulus, or toughness (Table 3.1). These results show that scCO2 treatment 
does not cause macroscopic changes to the mechanical properties of ElastEon TPU. 
 
Dynamic mechanical thermal analysis identified two characteristic peaks for solvent cast ElastEon – 
one at approximately -100oC and a second at -5oC. The lower temperature peak has been reported to 
correspond to motion in the polydimethylsiloxane phase, while the higher temperature peak has 
been assigned to motion in the α,ω-hydroxy-terminated polydimethylsiloxane end-group phase 
(Osman, Edwards et al. 2012). ScCO2 treatment in the absence of solute shifted the second peak to -
1oC suggesting a slight increase in the amount of hard segment dissolved within the soft domains, 
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which restricts the mobility of these sequences and therefore pushes the tan delta relaxation peak to 
higher temperatures. 
 
The control and scCO2 treated TPUs were also assessed by differential scanning calorimetry to 
determine whether there were significant changes in melting endotherms following CO2 treatment. 
The heating thermograms (Figure 3.1C) showed 2 endothermic peaks at 51.1 and 94.5oC. The 
scCO2 treated ElastEon exhibited similar endotherms, but an additional peak at 81.6
 oC was 
observed, which may be associated with mixing of hard and soft segments at the interface between 
hard and soft microdomains. This is consistent with the slight shift in tan delta observed, the 
decrease in tensile elastic modulus, and the reduction in hard microphase melting enthalpy (Table 
3.2).  While these changes are subtle, they suggest that the scCO2 has a compatabilising effect on 
  
 
Figure 3.1 Physical properties of ElastEon following scCO2 treatment.  (A) Stress-
strain curves. (B) Dynamic mechanical thermal analysis.  (C) Differential scanning 
calorimetry heating curve (arrows indicates additional endothermic peak in scCO2-treated 
film). (D) Differential scanning calorimetry cooling curve. 
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the ElastEon TPU morphology (phase mixing of hard and soft domains), but is not sufficient to 
affect the mechanical properties. 
 
Table 3.1 Mechanical properties of ElastEon TPU following scCO2 treatment 
Material 
Tensile Stress at Break 
(MPa) 
Tensile Strain at Break 
(%) 
Young’s 
Modulus 
Toughness 
Control 11.5 ± 1.3a) 750 ± 94 13.0 ± 0.3 56 ± 8 
scCO2 10.0 ± 2.0 746 ± 44 11.6 ± 0.8 48 ± 10 
a)Results are mean ± s.e.m, n = 5.  
 
3.2.2 Atomic force microscopy  
The microphase morphology of polymeric materials can be affected due to solvent annealing. Re-
structuring of the hard and soft domains within the polyurethane could well play a role in the 
release kinetics of drug molecules from the matrix due to variation in the hydrophilic/hydrophobic 
ratio across the film. To investigate if the scCO2 treatment affects the microphase morphology or 
topology of ElastEon near the surface, AFM images were acquired in tapping mode in which the 
topology of the materials was measured before and after scCO2 treatment. Figure 3.2A shows the 
ElastEon film displayed a relatively homogeneous surface map in terms of roughness, but that the 
surface became rougher after scCO2 treatment. The significant increase in roughness near the 
surface is likely caused by the mobility of polyurethane chains during scCO2 treatment rearranging 
to present the more hydrophilic hard segments towards the bulk solvent.  
 
Table 3.2 Differential scanning colorimetry analysis of ElastEon films following scCO2 
treatment. 
Material 
Heating Cooling 
Endotherm Peak Crystallization 
T1 
(oC) 
T2 
(oC) 
T3 
(oC) 
Hard Phase 
∆Hm(J/g) 
Peak 
(oC) 
Hc 
(J/g) 
Control 51.1 - 94.5 
9.3 
 
80.6 3.8 
scCO2 53.5 81.6 97.3 6.0 76.8 4.3 
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The effect of water on the microphase separation is also of importance since in situ rearrangement 
of the hard segments during exposure to physiological fluid may also affect diffusion of the drug 
molecules from the TPU film. To probe this further, the micromechanical properties of the ElastEon 
near the surface was measured by analysis of 32 × 32 force curve array over a 1 µm × 1 µm area. 
The force curve at each location in the map was analyzed and converted to modulus as a function of 
the applied force at 5 nm indentation depth. This analysis produced modulus maps with 
approximately 32 × 32 nm pixel resolution. Figure 3.2B illustrates changes of modulus maps of 
 
Figure 3.2 Atomic force microscopy images. (A) Height images of ElastEon before 
(Control) and after scCO2.treatment. (B) Changes in modulus maps (1 x 1 µm) at 5 nm 
depth for ElastEon incubated in PBS for up to 144 hr. 
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ElastEon and scCO2 treated ElastEon incubated in PBS over 6 days. The brighter colors in the maps 
represent a higher modulus (hard domains) while the darker colors represent a lower modulus (soft 
domains). The maps show that the distribution of hard domains (green color) at 5 nm depth 
increased over 6 days in PBS when the films were first treated with scCO2. ScCO2-induced 
enrichment of hard domains near the surface suggests that the material underwent restructuring near 
the surface, and also indicates that scCO2 promotes the mixing of hard segments in the soft domains 
near the surface, which leads to the significant migration of hard domains from subsurface to the 
surface when exposed to PBS. Such re-arrangement may manifest itself as modification in release 
behavior from the film since the diffusion of the drug will depend on its ability to move through the 
hard-soft regimes of the TPU. The release behavior of the drug is discussed in the following section.    
 
3.2.3 Drug loading and release from TPUs 
Three different model drugs, rhodamine B, 7-hydroxycoumarin and fluorescein (Figure 3.3A), were 
used to study the uptake and release profiles from TPU using two different encapsulation 
methodologies; solvent casting and scCO2-assisted impregnation. All three drugs were soluble in 
the polymer solvent DMAc and in scCO2. Figure 3.3B illustrates the uptake of each drug into 
ElastEon by scCO2 treatment. Rhodamine B and fluorescein reached a maximum concentration in 
the film at 400 µg of drug added to the reaction vessel. By contrast, the concentration of 7-
hydroxycoumarin in the film continued to increase up to 1 mg of drug in the vessel. The highest 
concentration reached for rhodamine B was 0.48 µg/mg compared to 0.90 µg/mg for fluorescein 
and 1.56 µg/mg for 7-hydroxycoumarin. The total amount of drug loaded in the films represents 
between 0.7 and 4% of the total amount of drug in the reaction vessel. These results suggest that 
ElastEon has a maximum loading capacity for rhodamine B and fluorescein, or that the solubility of 
these 2 drugs in scCO2 is limited. 
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To examine the homogeneity of drug loading, films were sectioned vertically for fluorescent 
microscopy. Figure 3.4 shows images of the ElastEon films loaded by solvent casting or by scCO2 
treatment. The cross-sectional fluorescent intensity was measured and quantified as relative 
fluorescence. For loading by both methods, there was an even distribution of each drug throughout 
the film, although occasionally, patchiness was evident for fluorescein (Figure 3.4, arrow) 
indicative of some variation in loading. These results show that scCO2 penetrated throughout the 
TPU films under the conditions used herein.  
 
 
 
Figure 3.3 Uptake of drugs into TPU with scCO2 treatment. (A) Structure of model 
drugs. (B) Uptake of drugs into ElastEon (mean ± s.e.m, n = 3). The left axis shows final 
concentration of drug in the films while the right axis shows total uptake for each drug. 
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The release of each of the model drugs from scCO2 loaded ElastEon over 120 hr is shown in Figure 
3.5, left panels. Rhodamine B release was biphasic and reached a maximum of 30% of the total 
amount of drug in the film. By contrast, 7-hydroxycoumarin efflux was rapid with the total drug 
released approaching 100% by 24 hr. For fluorescein, the initial rate of release was slower than for 
the other 2 drugs and efflux continued over 120 hr of the experiment.  Similar results were seen for 
the efflux of each drug following solvent casting (Figure 3.5, right panels).  
 
3.2.4 Modeling of drug release from ElastEon 
 
Figure 3.4 Fluorescent images of drug uptake into ElastEon by solvent casting or scCO2. 
Representative films are shown. Fluorescence intensity (arbitrary units) across each film was 
measured and quantified in the right panels (mean ± s.e.m, n = 3).  
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Each drug efflux profile was fitted to several different models that describe drug release from a 
solid matrix (Jokanovic, Colovic et al. 2013). These included the Avrami equation, Korsmeyer-
Peppas equation, Higuchi’s equation and Weibull equation. In addition, because some of the 
profiles showed biphasic release kinetics, data were also fitted to the following empirical equation 
(Combined Avrami-Lag equation), which describes the sum of two processes - initial diffusion 
using a modified Avrami equation and a delayed diffusion process with a lag time: 
 
Figure 3.5 Efflux of model drugs from scCO2 loaded (left panels) and solvent cast 
films (right panels).  Results are mean ± s.e.m, n = 3. Solid lines show results from 
mathematical modeling of the data (see text). 
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                                         𝑀𝑡 = 𝑀1(1 − 𝑒
(−𝑘1𝑡)) + 𝑀2/(1 + 𝑒
(−𝑘2(𝑡−𝑡𝑑)))                             (1) 
 
where Mt = amount of drug released by time t, M1 is the total amount of drug released by the initial 
process, M2 is the total amount of drug released by the delayed process, k1 and k2 are rate constants 
for each process, and Td = lag time. Different models were compared for goodness of fit using 
coefficient of determination (R2) and standard deviation (Sy.x) calculated as the square root of the 
sum of squared deviations divided by the degrees of freedom. The outcomes of modeling the release 
of drug from both scCO2 loaded and solvent cast ElastEon are summarized in Table 3.3 and the 
predicted values are shown in Figure 3.5 (solid lines).  
 
For rhodamine B, efflux occurred by 2 processes, an initial rapid releasing process and a slower 
process with a lag of 37-47 hr. These kinetics were observed regardless of the method of loading 
and the data were best described by equation 1 shown above. The first release process accounted for 
approximately 35% of the total drug efflux. By contrast, 7-hydroxycoumarin efflux was mono-
phasic and rapid, essentially complete within the first 24 hr. The data were best described by the 
Avrami equation (Jokanovic, Colovic et al. 2013): 
 
                                                             𝑀𝑡 =  𝑀0(1 − 𝑒
(−𝑘1𝑡
𝑛))                                                 (2) 
 
where M0 = amount of drug released, k1 is the efflux rate constant, and n = release exponent, which 
is dependent on the mechanism of drug efflux. The rate of release was faster following scCO2 
loading (k1 = 0.53 ± 0.03 hr
-1) compared to solvent casting ((k1 = 0.19 ± 0.03 hr
-1). The value of n 
(0.5 < n < 1) suggested that drug release was by non-Fickian or anomalous diffusion. 
 
The efflux of fluorescein was best described by equation 1 above indicative of 2 processes. Both 
processes accumulated similar amounts of fluorescein (M1 ~ M2 – Table 3.3). Compared with 
rhodamine B, the release of fluorescein was much slower and the delay (td) was significantly longer. 
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Table 3.3 Model parameters for the release of drug from scCO2 and solvent cast loaded ElastEon 
Drug Rhodamine B 7-Hydroxycoumarin Fluorescein 
  
scCO2 Solvent 
 
scCO2 Solvent 
 
scCO2 Solvent 
 
Model                    
(R2) 
CALEa)   
(0.976) 
CALE    
(0.976)  
Avrami 
(0.986) 
Avrami 
(0.975)  
CALE 
(0.987) 
CALE 
(0.997) 
Amount of drug in 
film (g)b) 
7.39 7.6  22.79 7.25  14.98 7.46 
Model 
Parameters 
M1 (g) 0.76 ± 0.13 0.91 ± 0.11 M0 (g) 21.9 ± 0.2 6.80 ± 0.12 M1 (g) 7.11 ± 1.00 2.51 ± 0.18 
k1 (hr
-1) 0.48  ± 0.14 0.17 ± 0.04 k1 (hr
-1) 0.53 ± 0.03 0.19 ± 0.03 k1 (hr
-1) 0.069 ± 0.019 0.06 ± 0.007 
M2(g) 1.40  ± 0.15 0.99 ± 0.12 n 0.71 ± 0.04 0.93 ± 0.10 M2(g) 7.88 ± 1.09 2.85 ± 0.23 
k2 (hr
-1) 0.09  ± 0.02 0.04 ± 0.01 
   
k2 (hr
-1) 0.038 ± 0.009 0.048 ± 0.005 
td (hr) 37  ± 4 47 ± 9 
   
td (hr) 73.1 ± 15.3 76.0 ± 4.4 
 
a)CALE = Combined Avrami-Lag equation – see text. Results are mean ± s.e.m. Parameter definitions: M0, M1, M2 = amount of drug in each 
compartment; k1, k2 = efflux rate constants; td = lag time; n = release exponent. 
 b)Mean of 3 observations. 
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Figure 3.6 Efflux of rhodamine B from different TPUs. (A) Structure the hard and soft 
segments for different TPUs. (B) Efflux of rhodamine B from the different TPUs. All data 
are mean ± s.e.m, n = 3. 
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3.2.5 Efflux of rhodamine B from different TPU’s 
The different efflux profiles for the 3 drugs indicated that they may interact differently with the 
components of the polyurethane. TPUs are comprised of hydrophilic hard segments and 
hydrophobic soft segments (Osman, Edwards et al. 2012). A major difference between the 3 drugs 
is their hydrophobicity. While 7-hydroxycoumarin is relatively hydrophilic (log(P) = 1.4), 
fluorescein is significantly less hydrophilic (log(p) = 3.9) and rhodamine B is the most hydrophobic 
(log(P) = 6.8). In addition, both rhodamine B and fluorescein have 4 aromatic rings whereas 7-
hydroxycoumarin only has 2 (Figure 3.3A). We next examined the release of the most hydrophobic 
drug, rhodamine B, from TPUs with different hard and soft segments (Figure 3.6A). ElastEon is 
composed of a 4,4-methylenediphenyl hard segment and a mixed macrodiol of α,ω-hydroxy-
terminated polydimethylsiloxane and polyhexamethylene oxide soft segment. Two other TPUs were 
examined. Pellethane comprises the same hard segment as ElastEon, but has a poly(tetramethylene 
oxide) soft segment, while Tecoflex has the same soft segment as Pellethane, and an aliphatic 4,4’-
methylenebis(cyclohexyl) (H12MDI) hard segment.  
 
  
Table 3.4 Model parameters for the release of drug from different TPUs 
TPU                       ElastEona) TecoFlex Pellethane 
 
R2  0.976 0.987 0.974 
Model 
Parameters 
M1 (%) 11.9 ± 1.5 73.3 ±10.9 26.4 ± 3.7 
k1 (hr
-1) 0.17 ± 0.04 0.62 ± 0.15 0.23 ± 0.05 
M2(%) 13.1 ± 1.6 29.1 ± 10.8 23.2 ± 3.7 
k2 (hr
-1) 0.04 ± 0.01 0.34 ± 0.28 0.06 ± 0.01 
td (hr) 47 ± 9 7.8 ± 4.2 36.6 ± 6.8 
 
a)Same data as shown in table 3, but efflux expressed as % total. Parameter definitions: M1, M2 = 
amount of drug in each compartment; k1, k2 = efflux rate constants; td = lag time. 
 
Figure 3.6B shows the efflux of rhodamine B over 120 hr from the three TPUs. The release profiles 
were well described by equation 1 above, suggesting 2 release processes.  The kinetic parameters 
are shown in Table 3.4. The rate of release from ElastEon and Pellethane was very similar (see k1 
and k2) but much slower than that for Tecoflex, where efflux was essentially complete by 24 hr. 
These results show that the rate and extent of drug release from TPUs is dependent on the 
composition of the hard and soft segments.  
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Water uptake may be one of factors that affect the drug release. To assess water uptake capability of 
different TPU films, moisture analyzer MF-50 was used. Figure 3.7B shows the minimum water 
uptake of ElastEon. Compare to ElastEon, water uptake of Tecoflex and Pellethane were significant 
higher (Figure 3.7B). On the basis of rhodamine B release from different TPUs (Figure 3.6B), water 
uptake may be one of the main factors that hinder the diffusion of rhodamine B from ElastEon. 
 
3.2.6 Effect of pore formers on the release of rhodamine B from ElastEon 
Effect of pore formers on the release of rhodamine B from ElastEon was studied by blending 
ElastEon solution with polyethylene glycol (PEG) (molecular weight 4,000 and 10,000) when 
casting films. Rhodamine B was co-casted with ElastEon solution. Compared to the efflux from 
ElastEon, the amount of rhodamine B released from films blended with PEG 4,000 or PEG 10,000 
was significantly increased (two-way ANOVA, P<0.05) (Figure 3.7A). The amount of rhodamine B 
released from ElastEon with PEG 4,000 was higher than from films with PEG 10,000 (two-way 
ANOVA, P<0.05) (Figure 3.7A). The cause of this may be due to the hydrophilicity of PEG. PEG 
with higher molecular weight has been shown to be more hydrophobic than PEG with lower 
molecular weight (Israelachvili 1997). Hydrophilic PEG 4,000 may enhance the penetration  
  
 
Figure 3.7 Efflux of rhodamine B from ElastEon blended with pore formers. (A) Efflux of 
rhodamine B from ElastEon blended with PEG 4,000 and 10,000. All data are mean ± s.e.m, n = 
3. Efflux of rhodamine B from ElastEon was used as control. Asterisks indicates a significant 
difference, two way ANOVA, P<0.05. (B) Water uptake of different thermoplastic 
polyurethanes. All data are mean ± s.e.m, n = 4. Asterisks denotes a significant difference 
compared to ElastEon (using student’s t-test, P<0.05). 
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of water into ElastEon, which results in the increased rate and extent of release. This result indicates 
that adding pore formers may be a good strategy to increase the drug release. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Efflux of rhodamine B from silicone Nusil MED 4860. (A) 
Efflux of different concentration rhodamine B from Nusil MED 4860. All 
data are mean ± s.e.m, n = 3. (B) Cross-section images of rhodamine B uptake 
by scCO2. 
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3.2.7 Release of rhodamine B from silicone Nusil MED 4860 films 
We also investigated the efflux of rhodamine B from silicone Nusil MED 4860 films. Nusil MED  
4860 is a biomedical grade elastomer, consisting of 30 wt % amorphous silica and 5 wt % dimethyl, 
methylhydrogen siloxane copolymer. This material contains polydimethylsiloxane, which is 
currently employed as insulation for implantable cochlear electrode arrays. PDMS-based TPU 
ElastEon is produced in an attempt to improve the material’s properties. The soft segment of 
ElastEon consists of PDMS, which is the same as the silicone MED-4860. However, silicone MED-
4860 is poorly soluble in most organic solvent and can be used in human implantation, Supercritical 
carbon dioxide technique may be a good method for loading therapeutics into silicone MED4860. 
Different concentration of rhodamine B (0.1%, 0.5%, 1%, wt/wt) was added into the scCO2 reaction 
vessel. The release profiles of rhodamine B from these silicone films were fitted by the following 
equation: 
 
                         
𝐶𝑡
𝐶0
= 1 − (
8
𝜋2
) 𝑒𝑥𝑝 [
−𝜋2𝐷𝑡
ℎ2
]                       (3) 
 
where Ct = concentration of drug released at time t, C0 = concentration of drug reached equilibrium, 
D = diffusion coefficient, h = thickness of the film. Figure 3.8A shows the efflux of rhodamine B 
from silicone Nusil MED 4860. The outcomes of the modeling indicate that the release followed a 
Fickian diffusion mechanism and the release reached equilibrium within 24 hours. Figure 3.8B 
shows the cross-section images of drug uptake into Nusil MED 4860 by scCO2. Rhodamine B was 
distributed evenly into the Nusil MED 4860 by scCO2. These results indicate that it is feasible to 
load drugs into silicone Nusil MED 4860 using scCO2.   
 
3.2.8 Mechanical properties of different polymers following scCO2 treatment 
The effect of scCO2 treatment on the mechanical properties of different polymers was examined by 
an Instron model 5543 universal testing machine. The mechanical properties of different polymers 
following scCO2 treatment is listed in Table 3.5. Compared with each polymer and polymer treated 
with scCO2, there were no statistical differences in tensile stress or strain at break, stiffness as 
measured by Young’s modulus, or toughness (Table 3.5). These results suggest that scCO2 
treatment does not cause statistic changes to the mechanical properties of polymers. 
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Table 3.5 Mechanical properties of different polymers following scCO2 treatment 
Materials 
Tensile stress at 
Break 
Tensile strain at 
Break 
Young's 
Modulus 
Toughness 
(MPa) (%) 
Tecoflex 11.4 ± 0.7 1213 ± 48 2.2 ± 0.4 51 ± 3 
Tecoflex scCO2 11.4 ± 1.0 989 ± 69 1.5 ± 0.2 40 ± 5 
Pellethane 40.3 ± 4.9 1047.5 ± 90.9 11.7 ± 0.7 181 ± 19 
Pellethane scCO2 40.4  ± 7.2 960 ± 102 11.2 ± 0.5 168 ± 49 
Nusil MED 4860 9.0 ± 2.2 799 ± 63 2.1 ± 0.7 40 ± 4 
Nusil MED 4860 
scCO2 
12.8 ± 1.1 775 ± 33 2.9 ± 0.3 36 ± 9 
Results are mean ± s.e.m, n = 5. 
 
3.3 Discussion 
In this study, we have shown that scCO2 treatment of TPU does not significantly affect macroscopic 
properties such as tensile strength, toughness or degree of stiffness. However, some reorganization 
of the polymeric structure was evident as seen by an additional endothermic peak in the differential 
scanning calorimetry heating curve. This peak at approximately 86oC may indicate additional 
mixing of the hard and soft segments of the TPU. At a microscopic level, differences were also 
observed. In particular, scCO2 treatment caused a shift in hard segments to the surface of the film, 
which was exacerbated following incubation in PBS. These results are also consistent with an 
increased mixing of the hard and soft segments.  It will be important to determine whether these 
changes induced by scCO2 treatment affect the biocompatibility and application of the TPU in 
biomedical devices. 
 
We examined the loading and release of 3 model drugs using scCO2 and compared the results with 
release profiles from TPU loaded by solvent casting. Firstly, scCO2 was able to generate a 
consistent and homogeneous loading of all 3 drugs in films that ranged in thickness from 100 to 200 
m as shown by fluorescence microscopy (Figure 3.4). However, less than 5% of the total drug 
accumulated in the films, indicating the method requires refinement for application to expensive 
therapeutics. Champeau et al found drug loading of aspirin into poly-L-lactide could achieve up to 
8.1% by scCO2 (Champeau, Thomassin et al. 2015). They suggested that polymer chain mobility 
during scCO2 treatment might be one of the main criteria that affect the diffusion of the drug into 
the matrix. In addition, the low solubility of most pharmaceutical compounds in scCO2 may be 
 
73 
 
another limiting factor (Davies, Lewis et al. 2008). Although not the aim of the present study, there 
have been several studies on the optimization of drug impregnation using scCO2 for advanced 
biomedical applications (Cortesi, Alessi et al. 2000, Davies, Lewis et al. 2008, Hussain and Grant 
2012). Second, the release of all 3 drugs was qualitatively similar following loading by scCO2 or 
solvent casting.  None of the drugs showed a burst effect, or very rapid release of near-surface drug, 
consistent with the homogenous loading shown in Figure 3.4. However, there were significant 
quantitative differences between the different loading techniques. For rhodamine B and fluorescein, 
efflux occurred from 2 kinetically distinct compartments. Release over the early time points was 
significantly faster when the films were impregnated using scCO2. This may be associated with the 
re-arrangement of the micromorphology of the TPU such that hard segments migrated to the surface 
of the film. Biphasic drug release from polymeric matrices has been previously reported both from 
films and as well as particles (Halliday, Moulton et al. 2012). The cause of this was not degradation 
of the film, as ElastEon has been shown to be highly stable in oxidative media representative of 
biological media and also under chronic in-vivo conditions (Martin, Warren et al. 2000, Simmons, 
Hyvarinen et al. 2004). The aromatic structure of rhodamine B and fluorescein compared to 7-
hydroxycoumarin suggested that these 2 drugs preferentially interact with the hard segments of the 
TPU. If this was the case, then the delayed release might be associated with movement of these 
segments to the surface of the film and the associated pi-stacking interactions that result. This 
hypothesis is supported by the release results obtained using Tecoflex, which has a hard segment 
where the 4,4-methylenediphenyl component is replaced with a less aromatic 4,4’-
methylenebis(cyclohexyl) structure. In this case, the pi-interactions between dye and matrix would 
be minimal and indeed, the release of rhodamine B was significantly more rapid (Figure 3.6B).  In 
summary, we have been able to show that model drugs can be loaded into polyurethane-based films 
using scCO2 with minimal changes to its mechanical properties. However, microphase 
rearrangement of the hard segments to the surface of the film during CO2-annealing may affect drug 
release. The overall efflux profiles were dependent on both the chemical structure of the drug and 
the composition of the polyurethane, which may allow for fine tuning of the drug release kinetics 
for in vivo applications. 
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Chapter 4 
 
In vitro controlled release of therapeutic 
peptides from polyurethane films  
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4.1 Introduction 
 
In this chapter, we have investigated the release of a range of peptides from thermoplastic 
polyurethanes (TPUs) containing different soft and hard segments. The purpose of this study is to 
understand how therapeutic peptides might be incorporated into and released from TPUs films in a 
controlled, time-dependent manner.  
 
The therapeutic utility of peptides has been drawing great attention as a result of their good 
biocompatibility, high selectivity and potency (Zhang, Eden et al. 2012). Despite rapid progress in 
manufacture of novel therapeutic peptides, the effective delivery of these peptides to the desired site 
in body remains a major challenge due to issues such as poor stability, low permeability and rapid 
clearance (Gupta 2013).  To improve peptide drug efficiency, some delivery systems have been 
developed (Park, Kim et al. 2014). To date, there are very few studies that have investigated 
delivery of biological peptides using TPUs. In addition, few peptide delivery systems have been 
commercialized. Therefore, it is worthy of exploration for design of peptide delivery systems to 
improve therapeutic effect of peptides and their clinical applications. 
 
In this chapter, we have specifically investigated the role of TPUs as drug delivery matrices for 
peptidic C5a receptor (C5aR) antagonists. Peptidic C5aR antagonists have been shown to inhibit 
complement activation by C5a and C5aR interaction (Woodruff, Nandakumar et al. 2011). These 
peptides have displayed potential therapeutic value in a range of animal models of inflammatory 
diseases (Woodruff, Crane et al. 2006, Boor 2007, Qu, Ricklin et al. 2009). However, conventional 
routes of administration have shown rapid elimination (Strachan, Shiels et al. 2001, Morgan, 
Bulmer et al. 2008). In vivo delivery of these peptides using TPUs may prolong their bioavailability, 
reduce injection frequency and attenuate biomaterial-induced complement-mediated inflammatory 
responses. Due to the application of TPUs in implanted devices, the novel approach reported here 
has broad application to drug delivery using TPUs either alone or as part of an implantable device. 
These peptide-loaded thermoplastic polyurethanes could contribute to developing strategies that 
improve the pharmacological utility of peptides as therapeutics. 
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4.2 Results 
 
4.2.1 Effect of elevated temperature and organic solvents on the stability of C5aR antagonists 
Peptides, PMX53 and JPE1375, were used to investigate in vitro release from TPU films. Figure 
4.1A and B show the chemical structure of PMX53 and JPE1375, respectively.  Cyclic peptide 
PMX53 and linear peptide JPE1375 act as high affinity antagonists of C5aR signaling. Liquid 
chromatography-mass spectrometry (LC-MS) analysis of both peptides is shown in Figure 4.2A and 
B. Both peptides eluted from the column at 7.11 min. The positively charged PMX53 and JPE1375 
underwent extensive fragmentation. Among these, fragment 70.100 Da of PMX53 and fragment 
197.300 Da of JPE1375 showed the highest intensity and were used to analyse data.  
 
We first investigated the effect of elevated temperature and organic solvents on the stability of these 
two peptides, as both of these parameters are required to cast and dry polyurethane films. C5aR 
antagonists were incubated with or without Tecoflex 80A (T80A) in dimethylacetamide (DMAc) 
solutions at 60°C for 5 h and at 80°C for 5 h. Figure 4.3A shows that the linear peptide JPE1375 
was not stable after the incubation, while PMX53 was stable.  
 
We also examined the stability of these two peptides in organic solvents by incubating them in 
methanol (MeOH), dichloromethane (DCM), tetrahydrofuran (THF) and dimethylacetamide 
(DMAc) respectively for 4 h. The reason why we chose these solvents is that they are widely used 
to dissolve polymers. Figure 4.3B shows JPE1375 was not stable in DMAc and THF, but was stable 
in MeOH and DCM. However, the cyclic PMX53 was stable under all conditions (Figure 4.3B). 
Figure 4.1 Chemical structures of C5aR antagonists. (A) PMX53. (B) JPE1375. 
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Dimethylacetamide (DMAc) is a widely used organic solvent to dissolve polyurethanes. Figure 
4.3C shows the mass spectrometry of JPE1375 in methanol (MeOH) and DMAc. JPE1375 in  
  
 
Figure 4.2 Representative LC-MS analysis of C5aR antagonists. (A) 
PMX53. Retention time was 7.11 min. The 3 most intense product ions, 70.100 
Da, 120.100 Da, and 159.200 Da, were selected. Optimal product ion mass 
70.100 Da of PMX53 was used to analyse data. (B) JPE1375. Retention time 
was 7.11 min. The 4 most intense product ions, 197.300 Da, 225.100 Da, 
70.100 Da, and 390.200 Da, were selected. Optimal product ion mass 197.300 
Da of JPE1375 was used to analyse data. 
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MeOH was used as control. More peaks were shown for JPE1375 in DMAc compared to control 
(Figure 4.3C). This result suggests that JPE1375 might be aggregated when incubated in DMAc, 
and indicates that the conventional conditions for casting TPU films are not suitable for preparing 
linear peptide-loaded TPU films. 
  
 
Figure 4.3 Effect of elevated temperature and organic solvents on the stability of 
C5aR antagonists. (A) Effect of elevated temperature on the stability of JPE1375 and 
PMX53 by incubating with or without Tecoflex 80A in DMAc at 60°C for 5 h and at 80°C 
for 5 h. (B) Effect of various organic solvents on the stability of JPE1375 and PMX53 by 
incubating peptides in various solvents for 4 h at room temperature. Closed bar represents 
JPE1375. Open bar represents PMX53. Results are mean ± s.e.m, n = 3. Asterisk indicates 
significant difference, student’s t-test, P<0.05. (C) Mass spectrometry of JPE1375 in 
methanol (left) and in dimethylacetamide (right). JPE1375 in MeOH was used as control. 
Target ion mass of JPE1375 is 955.5 Da. 
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Milder conditions were required to retain the bioactivity of peptides, including lower temperature 
and mild organic solvents. The physical structures of peptides play an important role on the stability 
of peptides. The cyclic structure of peptides (PMX53) is more stable under adverse conditions 
compared with the linear structure (JPE1375). In this study, we used dichloromethane to prepare 
peptide-loaded TPU films at room temperature, as this solvent can be easily evaporated at room 
temperature, dissolve TPUs and maintain the stability of both peptides (Figure 4.3B).  
 
4.2.2 Calibration curves of C5aR antagonists in different media 
To investigate in vitro release of peptides from TPU films, we first used LC-MS to measure the 
standard curves of PMX53 and JPE1375 in different media, MilliQ H2O, PBS and 10% FBS-RPMI. 
PBS (pH = 7.4) was used as a release medium to match the osmolarity and ion concentration of the 
human body. The release medium 10% FBS-RPMI was used as it contains proteins, maintains pH = 
7.4 and osmolarity. Known amounts of each peptide were added into each medium (400 µl) to 
prepare standards for calibration curves. Standards in MilliQ H2O and PBS were freeze-dried and 
re-dissolved in MeOH. For standards in 10% FBS-RPMI, acetonitrile containing 1% formic acid 
were added to precipitate proteins and avoid degradation of peptides. Supernatant of standards in 10% 
FBS-RPMI was withdrawn and freeze-dried. Figure 4.4A shows the standard curve of PMX53 in 
 
Figure 4.4 Standard curves of C5aR antagonists in different media. (A) Standard curves 
of PMX53 in different media. Symbol ●: PMX53 in MilliQ H2O, linear regression y = 1229 
x, symbol ■: PMX53 in 10% FBS-RPMI, linear regression y = 286.3 x, symbol ▼: PMX53 
in PBS, linear regression y = 370.2 x. (B) Standard curves of JPE1375 in different media. 
Symbol ●: JPE1375 in MilliQ H2O, linear regression y = 5014 x, symbol ■: JPE1375 in 
10% FBS-RPMI, linear regression y = 1990 x, symbol ▼: JPE1375 in PBS, linear regression 
y = 1776 x. Asterisk indicates a significant difference compared peptides in 10% FBS-RPMI 
and PBS to peptides in H2O, respectively, two-way ANOVA, P<0.05. 
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different media. For the same concentration of PMX53, the peak area in PBS and 10% FBS-RPMI 
were significantly lower than in H2O (two-way ANOVA, P<0.05) (Figure 4.4A). Similar results 
were seen for JPE1375 (Figure 4.4B). These results show that the same concentration peptides had 
different signal intensity in different media. For further release studies, peptide concentration was 
measured against each standard curve prepared in different media using the same method.  
 
4.2.3 In vitro release of C5aR antagonists from different TPUs 
The efflux of C5aR antagonists from TPUs is shown in Figure 4.5. TPUs were dissolved in 
dichloromethane (5 % wt/v) and co-casted with C5aR antagonists (50 µg) at room temperature. 
Films were cut into 1 cm x 1 cm before immersing in PBS. The efflux was conducted in PBS at 
37oC on a rotating wheel. Samples (400 µl) at each time point were collected, freeze-dried, and re-
dissolved in MeOH (50 µl). The concentration of each sample was measured by LC-MS against a 
calibration curve. Figure 4.5A shows the efflux of PMX53 and JPE1375 from different TPUs. The 
efflux of JPE1375 approached equilibrium within 24 h and reached about 30% of total amount in 
the films over 3 days from Tecoflex 80A (T80A). The rate and extent of PMX53 efflux from T80A 
were significantly higher than for JPE1375 (two-way ANOVA, P<0.05) (Figure 4.5A). The efflux 
of both peptides from T80A was significantly higher than from ElastEon 5325 (E5325) (two-way 
 
Figure 4.5 Efflux of C5aR antagonists from different polyurethane films in PBS at 
37oC. (A) Efflux profiles of PMX53 and JPE1375 from Tecoflex 80A (T80A) and 
ElastEon 5325 (E5325). The efflux profiles of JPE1375 released from T80A and PMX53 
from E5325 were compared to PMX53 from T80A. The efflux profile of JPE1375 released 
from T80A was compared to from E5325.  (B) Efflux profiles of PMX53 from Tecoflex 
80A (T80A), Pellethane 90A (P90A) and ElastEon 5325 (E5325). The efflux profiles of 
PMX53 released from P90A and E5325 were compared to from T80A.  Asterisk indicates 
a significant difference, two-way ANOVA, P<0.05. Results are mean ± s.e.m, n = 3. 
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ANOVA, P<0.05) (Figure 4.5A). The efflux of both peptides from E5325 was less than 5% (Figure 
4.5A).  
 
Due to the instability of JPE1375 in different organic solvents, PMX53 was chosen to investigate 
the release from TPUs prepared using other solvents than DCM. TPUs were dissolved in 
tetrahydrofuran (THF) (5 % wt/v) and co-casted with PMX53 (50 µg) at room temperature. Figure 
4.5B shows the efflux of PMX53 over 72 h from three different TPUs in PBS at 37oC. The efflux of 
PMX53 from T80A approached about 80% over 48 h and maintained the equilibrium (Figure 4.5B). 
The rate and extent of PMX53 released from T80A were significantly higher than Pellethane 90A 
(P90A) or E5325 (two-way ANOVA, P<0.05) (Figure 4.5B). Minimum release (about 2%) was 
observed for PMX53 from E5325 (Figure 4.5B). These results indicate that the efflux of peptides 
could be determined by the composition of hard and soft segments of TPUs. 
 
4.2.4 Interaction of C5aR antagonists with ElastEon 5325 
To investigate whether the minimum release of C5aR antagonists from E5325 was caused by the 
binding of peptides to E5325, we cast blank E5325 films and immersed films (1cm x 1 cm) in 
peptide solutions (1000 ng/ml). Films were incubated with each peptide at 37oC for predetermined 
time. The amount of peptides left in MilliQ H2O was measured by LC-MS. Figure 4.6A shows the 
 
Figure 4.6 Interaction of C5aR antagonists with E5325. (A) Interaction of JPE1375 with 
E5325 films. JPE1375 solution without E5325 was used as control. (B) Interaction of 
PMX53 with E5325 films. PMX53 solution without E5325 was used as control. For both 
peptides, there was no significant difference between peptide solutions and peptide 
solutions with E5325 films, two-way ANOVA, P>0.05. Results are mean ± s.e.m, n = 3. 
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interaction of JPE1375 with E5325. JPE1375 solution without E5325 films was used as control. 
Compared to JPE1375 solution without films, there was no statistically difference of JPE1375 
solution with E5325 films (two-way ANOVA, P>0.05). Similar result was seen for PMX53 (Figure 
4.6B). These results indicate that the major factor hindered the efflux of peptides from E5325 was 
not due to the binding of peptides to E5325. The main reason why E5325 exhibits minimum release 
of peptides may be due to water uptake. The minimum water uptake of E5325 may limit the 
dissolution and diffusion of peptides from films.  
 
4.2.5 Effect of film thickness and drug loading amount on the release profiles  
The effect of film thickness and drug loading amount on the release profiles from TPU films was 
investigated.  Tecoflex 80A (T80A) was co-casted with the same amount of peptides (50 µg) into 
different thickness (0.1 mm, 0.2 mm). Films with different thickness were cut into 1 cm x 1 cm and 
incubated in MilliQ H2O at 37
oC for efflux. In this chapter, most efflux was conducted in PBS, the 
reason why MilliQ H2O used here was due to the absence of salts in MilliQ H2O. Samples can be 
injected directly into LC-MS column without separating salts. Figure 4.7A shows the efflux profiles 
of JPE1375 from 0.1 mm thick and 0.2 mm thick T80A. The initial rates of JPE1375 were similar, 
but the extent of efflux from 0.1 mm thick films was significantly higher than from 0.2 mm thick 
films (two-way ANOVA, P<0.05) (Figure 4.7A). Similar results were seen for PMX53 from T80A 
at 0.1 mm and 0.2 mm thickness (Figure 4.7B).  These results indicate that increasing thickness of 
films may lead to decrease in the extent of drug release (Figure 4.7A and B). 
 
Different amounts of peptides (50 µg, 250 µg, 500 µg) were co-casted into the T80A films (0.1 mm 
thick). Figure 4.7C shows the efflux of different amounts of JPE1375 from T80A. The rate and 
extent of JPE1375 with 250 µg and 500 µg loading were significantly higher than from films with 
50 µg loading (two-way ANOVA, P<0.05) (Figure 4.7C). However, there was no significant 
difference in efflux between 250 µg loading and 500 µg loading (Figure 4.7C). Similar results were 
seen for PMX53 with different amounts of loading (Figure 4.7D). These results suggest that the 
thickness of the films and drug loading amount may affect the efflux profiles.  
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Figure 4.7 Effect of film thickness and drug loading amount on the efflux of C5aR 
antagonists from Tecoflex 80A (T80A) films. (A) Release profiles for JPE1375 from 
T80A at 0.1 mm and 0.2 mm thickness. (B) Release profiles for PMX53 from T80A at 
0.1 mm and 0.2 mm thickness. (C) Release profiles for JPE1375 from T80A with 50 
µg, 250 µg, and 500 µg loading. (D) Release profiles for PMX53 from T80A with 50 
µg, 250 µg, and 500 µg loading. Asterisk indicates a significant difference, two-way 
ANOVA, P<0.05. Results are mean ± s.e.m, n = 3.  
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4.2.6 In vitro release of PMX53 from different TPUs  
Tecoflex TPUs and Pellethane TPUs offer a wide range of properties for medical products and are 
available in a variety of hardness. The hardness of materials is determined by the ratio of hard to 
soft segments or the size of hard segments. In this study, Pellethane 83A (P83A), Pellethane 90A 
(P90A), Tecoflex 72A (T72A) and Tecoflex 80A (T80A) were used. Pellethane TPUs comprise a 
4,4-methylenediphenyl hard segment and a poly(tetramethylene oxide) soft segment, while 
Tecoflex TPUs have an aliphatic 4,4’-methylenebis(cyclohexyl) (H12MDI) hard segment and the 
same soft segment as Pellethane TPUs. The number in each TPU’s name represents the value of 
hardness. For harder materials, a larger number is used. ‘A’ represents durometer A scale, which is 
a method for measuring the hardness of polyurethanes.  
 
We used PMX53 as a model peptide and investigated the effect of hardness of TPUs on release 
profiles. All TPUs were dissolved in dichloromethane (5% wt/v) and co-casted with PMX53 (50 
µg). Efflux was conducted by immersing films (1 cm x 1 cm) in PBS at 37oC. Figure 4.8 shows the 
release of PMX53 from Tecoflex TPUs and Pellethane TPUs. Despite Tecoflex TPUs and 
Pellethane TPUs consisting of different composites of hard segments (shown in Table 2.2, Chapter 
2), the efflux profiles from Tecoflex series and P83A were similar (two-way ANOVA, P>0.05) 
 
Figure 4.8 Efflux of PMX53 from different TPUs. The release from 
Pellethane 90A, Pellethane 83A, Tecoflex 72A and Tecoflex 80A was 
compared. Asterisk indicates a significant difference, two-way ANOVA, 
P<0.05. Results are mean ± s.e.m, n = 3. 
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(Figure 4.8). The release from Tecoflex series and P83A approached about 40% over 72 h (Figure 
4.8). The release from P90A was statistically different from other release profiles (two-way 
ANOVA, P<0.05) (Figure 4.8). The efflux from P90A reached about 28% over 72 h (Figure 4.8). 
These results indicate that the hardness of TPUs may play an essential role in the efflux of peptides.  
 
4.2.7 Release of C5aR antagonists from Tecoflex 80A in different media 
We chose Tecoflex 80A (T80A) to investigate the release of peptides in different media (MilliQ 
H2O, PBS and 10% FBS in RPMI). T80A was co-casted with peptides (50 µg). All the samples 
were measured by LC-MS against each standard curve prepared in different media using the same 
method. 
 
Figure 4.9A shows the release of PMX53 from T80A in different media. Compared to the release in 
MilliQ H2O, the extent of release increased to around 50% in PBS and approached about 100% in 
10% FBS-RPMI over 3 days (Figure 4.9A). In the presence of 10% FBS, the release of PMX53 
approached about 60% within 4 h (Figure 4.9A). , because diffusion is dependent on water uptake 
as well as osmotic effects of different solutes. Figure 4.9B shows the release of JPE1375 from 
T80A in different media. Similar to PMX53, the extent of JPE1375 released in PBS was 
significantly higher than in MilliQ H2O (two-way ANOVA, P<0.05) (Figure 4.9B). However, for 
the release in 10% FBS-RPMI, the extent of released JPE1375 increased to about 20% over 24 h, 
and then decreased to about 2% (Figure 4.9B). This suggests that JPE1375 may be degraded in 
serum or may bind with proteins in the medium. The increase in the first 24 h may be because the 
rate of efflux was higher than the rate of degradation (Figure 4.9B). Due to the instability of 
JPE1375, samples and standard curves were treated with acetonitrile containing 1% formic acid 
immediately when collected or prepared. 
 
Figure 4.9 C shows the fluorescent images of FITC-labeled FBS penetration into T80A. FBS was 
labeled with FITC. Unbound FITC was separated by PD-10 desalting column. FITC- 
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Figure 4.9 Release of C5aR antagonists from Tecoflex 80A (T80A) in different 
media. (A) Release of PMX53 from T80A in MilliQ H2O, PBS and 10% FBS-RPMI. 
The efflux in PBS and MilliQ H2O were compared to in 10% FBS-RPMI. (B) Release 
of JPE1375 from T80A in MilliQ H2O, PBS and 10% FBS-RPMI. The release in 10% 
FBS-RPMI and MilliQ H2O were compared to in PBS. Asterisk indicates a significant 
difference, two-way ANOVA, P<0.05. Results are mean ± s.e.m, n = 3. (C) 
Fluorescent images of FITC-labeled FBS diffusion into T80A. T80A films incubated 
in the elute of free FITC was used as control. 
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labeled FBS was collected and examined by a NanoDrop. T80A films were incubated in FITC-
labeled FBS solution for 1 h at room temperature in dark. For control samples, FITC solution 
without FBS was separated by PD-10 desalting column.   The same time point eluate as that of 
FITC- labeled FBS was collected.  T80A films were incubated in the eluate solution under the same 
condition. T80A films were then sectioned vertically into thin strips for viewing using an OLYMPUS 
IX51 fluorescence microscope.  Figure 4.9C shows that FITC-labeled FBS distributed on the edge of 
T80 films after 1 h incubation. This result indicates that FBS in the release medium may penetrate 
into T80 films. These results suggest that for in vivo drug delivery application, peptides should have 
good stability in serum. 
 
4.2.8 Effect of blending TPUs on the release profiles of C5aR antagonists 
To better control the efflux of peptides from TPUs, we investigated the effect of blending TPUs on 
the release profiles of peptides. Different amounts of Tecoflex 80A (T80A) and ElastEon 5325 
(E5325) were blended and co-casted with peptides (50 µg) at room temperature. The efflux was 
conducted in 10% FBS-RPMI at 37oC.  Previous results have shown that PMX53 but not JPE1375 
was stable in the presence of serum (Figure 4.9A and B). Poor serum stability of peptides leads to 
the low bioactivity of peptides in vivo (Bruno, Miller et al. 2013). Therefore, we primarily 
investigated the efflux of PMX53 from blended TPUs in 10% FBS-RPMI.  
 
Figure 4.10A shows the efflux of PMX53 from the blended TPUs over 3 days in 10% FBS-RPMI. 
The initial rate and extent of drug release was significantly suppressed by increasing the ratio of 
E5325 in T80A (Figure 4.10A). The efflux profile was linear from 75% T80A (Figure 4.10A). The 
efflux extent from 50% T80A was statistically lower than from T80A (two-way ANOVA, P<0.05) 
(Figure 4.10A). A prolonged PMX53 release profile over 21 days is shown in Figure 4.10B from 50% 
T80A. However, there was still minimum efflux of PMX53 from E5325 over 21 days in 10% FBS-
RPMI (Figure 4.10B). These results suggest that the blending of T80A and E5325 may better 
control the release of PMX53 in 10% FBS-RPMI.  
 
Figure 4.10C shows the efflux of JPE1375 from the blended TPUs at 4 h in 10% FBS-RPMI. 
JPE1375 was co-casted with blended T80A-E5325 and released for 4 h in 10% FBS-RPMI. The 
presence of E5325 in T80A also affects the efflux of JPE1375 from films (Figure 4.10C). Similar to 
the efflux of PMX53, the initial extent was suppressed by increasing the ratio of E5325 in T80A 
(Figure 4.10C). Due to the instability of JPE1375 in 10% FBS-RPMI, no further measurement was 
conducted over 4 h. 
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4.2.9 In vitro bioactivity of released C5aR antagonists 
After in vitro release studies, we investigated if the released C5aR antagonists from Tecoflex 80A 
(T80A) were still biologically functional by measuring Ca2+ concentration mobilization in U937 
 
Figure 4.10 Effect of blending TPUs on the release profiles of C5aR antagonists. (A) 
Efflux of PMX53 from blended films over 3 days in 10% FBS-RPMI. The efflux from 
T80A was compared to from 50% T80A. Asterisk indicates a significant difference, two-
way ANOVA, P<0.05. (B) Efflux of PMX53 from 50% T80A over 21 days in 10% FBS-
RPMI. (C) Efflux of JPE1375 from blended films at 4 h in 10% FBS-RPMI. All results are 
mean ± s.e.m, n = 3. 
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cells. The functional C5aR antagonists can compete with C5a to bind with C5aR inhibiting 
downstream signaling that leads to inhibition of Ca2+ mobilization (Schnatbaum, Locardi et al. 
2006).  
 
T80A was dissolved in dichloromethane (5% wt/v) and was co-casted with C5aR antagonists (50 
µg). Release was conducted by immersing films (1 cm x 1 cm) in MilliQ H2O at 37
oC for 72 h. 
Samples at 72 h were collected, freeze-dried and re-dissolve in PBS (130 µl). Standard samples (0.1 
µM and 1 µM C5aR antagonists) were prepared in PBS (130 µl). U937 cells were differentiated by 
treating with dibutyryladenosine monophosphate (1 mM) for 48 h. Differentiated U937 cells were 
centrifuged to remove the growth medium and resuspended in Fluo-4 NW dye solution. Cells 
(125,000 cells per well) in Fluo-4-NW dye solution were plated in the 96-well plate and incubated 
for 30 min at 37oC, and then centrifuged. The same volume (25µl) of standard C5aR antagonists 
 
 
Figure 4.11 In vitro bioactivity of released C5aR antagonists by measuring 
intracellular calcium concentration [Ca2+] changes. Differentiated U937 cells were 
incubated in Fluo-4 NW dye solution. Standard C5aR antagonists (0.1 µM, 1 µM), released 
peptides, and PBS were added into wells respectively. After 10 min, 10 nM C5a were 
added into each well. The changes in the intracellular Ca2+ concentration were measured. 
(A) Application of 1 µM PMX53 significantly inhibited [Ca2+] elevation compared with 
0.1 µM PMX53 and control. Application of PMX53 released from T80A significantly 
inhibited [Ca2+] elevation compared with 0.1 µM PMX53 and control. Application of PBS 
was used as control. (B) Similar to (A), application of 1 µM JPE1375 significantly 
inhibited [Ca2+] elevation compared with 0.1 µM JPE1375 and control. Application of 
JPE1375 released from T80A significantly inhibited [Ca2+] elevation compared with 0.1 
µM JPE1375 and control. Application of PBS was used as control. All data are mean ± 
s.e.m, n = 3. Asterisk indicates a significant difference, student’s t-test, P<0.05.  
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(0.1 µM and 1 µM C5aR antagonists), released peptides, and PBS were added into wells, 
respectively. After 10 min, 10 nM C5a were added into each well. The changes in the intracellular 
Ca2+ concentration were measured at an excitation wavelength of 495 nm and an emission 
wavelength of 516 nm using a fluorescence microplate reader. 
 
Figure 4.11A shows the in vitro bioactivity of released PMX53 by measuring intracellular calcium 
concentration changes. The two left columns (Figure 4.11A) represent the standard effect of 
PMX53 (0.1 µM and 1 µM) on cellular response to C5a. Control (100% response) is the effect of 
PBS on cellular response to C5a (Figure 4.11A). The effect of released PMX53 from T80A was to 
significantly inhibit cellular calcium response compared to 0.1 µM PMX53 and control (Figure 
4.11A). Similar results were found for the released JPE1375 from T80A (Figure 4.11B). The release 
results (Figure 4.9) show that the release of both peptides on 72 h was around 0.1-0.2 µM, which 
was able to reduce to about 1%-10% calcium release. The release results were corresponded to this 
antagonism study. These results indicate that both of the released peptides were able to block the 
cellular response to C5a and maintained their in vitro bioactivity. 
 
4.2.10 In vitro release of PMX205 and PMX201 from different TPUs 
We have demonstrated that the cyclic peptide PMX53 had better stability in the presence of serum, 
elevated temperature, and organic solvents, compared to the linear peptide JPE1375 (Figure 4.3 and 
Figure 4.9). We, therefore, investigated the efflux of another two cyclic peptides, PMX201 (AcF-
[OP(D-Cha)WCit]) and PMX205 (hydrocinnamate-[OP(D-Cha)WR]) (Proctor, Woodruff et al. 
2006). These two analogs of PMX53 were designed with increased lipophilicity and target C5aR for 
treatment of various inflammatory conditions (Proctor, Woodruff et al. 2006). PMX205 has been 
shown to attenuate inflammation using both rat and murine models (Woodruff, Crane et al. 2006, 
Fonseca, Ager et al. 2009), while PMX201 has demonstrated lower antagonist potency compared to 
PMX53 (Proctor, Woodruff et al. 2006).  
 
Figure 4.12 shows the chemical structures of PMX201 and PMX205. Compared to PMX53, 
PMX205 has an entracyclic hydrocinnamate moiety, and Arg in PMX201 is substituted with an 
uncharged citrulline residue. 
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Firstly, the LC-MS analysis of PMX201 and PMX205 is shown in Figure 4.13. Positively charged 
PMX201 and PMX205 were fragmented. Fragments 70.100 Da of both PMX201 and PMX205 
were used for further analysis. The retention time of PMX201 and PMX205 were 7.44 min and 7.27 
min, respectively, indicating that PMX201 was more hydrophobic than PMX205. Studies have 
shown that increasing lipophilicity in these compounds did not result in increased blood levels 
(Proctor, Woodruff et al. 2006). The drug delivery systems may prolong or increase blood levels, as 
the difference of lipophilicity may affect the interaction between peptides and TPUs and further 
affect the efflux profiles. 
Figure 4.12 Chemical structures of cyclic PMX family. (A) PMX53. (B) PMX205. 
(C) PMX201. Red boxed areas show structural changes compared with PMX53. 
Adapt from (Busolo, Fernandez et al. 2010) 
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The efflux of these two analogs of PMX53 from different TPUs was assessed. Both peptides (50 µg) 
were dissolved in methanol and co-cast with films at room temperature. The efflux was conducted 
 
Figure 4.13 Representative LC-MS analysis of PMX201 and PMX205. (A) 
PMX201. Retention time was 7.44 min. The 3 most intense product ions, 70.100 
Da, 159.200 Da, and 223.200 Da, were selected. Optimal product ion mass 70.100 
Da of PMX201 was used to analyse data. (B) PMX205. Retention time was 7.44 
min. The 3 most intense product ions, 70.100 Da, 159.200 Da, and 223.200 Da, 
were selected. Optimal product ion mass 70.100 Da of PMX205 was used to 
analyse data. 
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in PBS at 37oC over 72 h. Figure 4.14A shows the efflux profiles from Tecoflex 80A (T80A). The 
efflux profiles of PMX201 and PMX205 from T80A were similar to the profile of PMX53 (two-
 
Figure 4.14 Efflux of cyclic PMX analogs from different TPUs. (A) Release of all 
three peptides (PMX53, PMX201, and PMX205) from Tecoflex 80A (T80A). (B) 
Release of all three peptides from blended T80A and ElastEon 5325 (1:1 wt/wt ratio). 
(C) Release of all three peptides from Pellethane 90A. (D) The relationship between 
cumulative release from T80A at 72 h and hydrophobicity. Hydrophobicity is retention 
time (RT) of LC-MS analysis. Linear regression y=104.9 x - 695.5, R2=0.8206. 
Asterisk indicates a significant difference, two-way ANOVA, P<0.05. All results are 
mean ± s.e.m, n = 3. 
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way ANOVA, P>0.05) (Figure 4.14A). When T80A was blended with E5325 (1:1 wt/wt ratio), 
there was no statistical difference in the efflux of both peptides and PMX53 (two-way ANOVA, 
P>0.05) (Figure 4.14B). The cumulative release of all these three peptides from blended films 
approached about 40% over 3 days, while release from T80A approached about 70%. Figure 4.14C 
shows the efflux of all three peptides from Pellethane 90A (P90A). The rate and extent of PMX205 
released were statistically lower than the rate and extent of PMX201 and PMX53 over 72 h (Figure 
4.14C). These results indicate that PMX201, PMX205 and PMX53 may have different interaction 
with hard segment of Pellethane TPUs, as Tecoflex TPUs and Pellethane TPUs consisting of 
different composites of hard segment and same composites of soft segment (shown in Figure 3.6, 
Chapter 3), 
 
Figure 4.14D illustrates the relationship between cumulative release from T80A at 72 h and 
hydrophobicity (retention time of LC-MS analysis, RT). There was a significant relationship 
between cumulative release at 72 h and hydrophobicity (R2=0.8206, P<0.0001).  This result 
suggests that hydrophobicity of peptides may contribute to the efflux of peptides from TPUs. 
 
4.2.11 Effect of blending TPUs with nanoclays on the efflux profiles of PMX53 
Nanoclays are one of most widely used materials in the manufacture of polymer-clay composites 
due to their properties, including high specific surface area, negligible toxicity and high adsorption 
capacity (Choy, Choi et al. 2007). In biomedical applications, they were recently used for drug and 
gene delivery (Suresh, Borkar et al. 2010), protein adsorption (Mortimer, Butcher et al. 2014), anti-
microbial function (Busolo, Fernandez et al. 2010), and in polymer-clay composites (Nitya, Nair et 
al. 2012). Since polymers blended with nanoclays have been shown to improve the mechanical 
properties (Pizzatto, Lizot et al. 2009), nanoclays have been incorporated into polymers for drug 
delivery (Ha and Xanthos 2011, DeLeon, Nguyen et al. 2012). Incorporation of nanoclays into 
polymers may reduce the porosity of polymers and hinder water penetration, which may affect the 
diffusion of drugs through the polymers (Suresh, Borkar et al. 2010). To further modify the efflux 
profiles, we blended TPUs with different nanoclays during casting TPUs.  
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Figure 4.15 Effect of nanoclays on the efflux of PMX53 from TPUs. (A) Interaction 
between PMX53 with 7 different nanoclays, Lucentite SWN (LSWN), Laponite BDS 
(LBDS), Lacontite SWN (LaSWN), Laponite OG (LOG), Laponite WXFP (LWXFP), 
Laponite WXFN (LWXFN) and Somasif ME100 (SME100). PMX53 was incubated 
with each nanoclay at 37oC in MilliQ H2O for 1 h. The same treatment of PMX53 
without nanoclays was used as control. Asterisk indicates a significant difference, 
student’s t-test, P<0.05. (B) Release of PMX53 from T80A blended with 10% (wt/wt) 
LSWN in MilliQ H2O. The release from T80A was used as control. Asterisk indicates a 
significant difference, two-way ANOVA, P<0.05. (C) Release of PMX53 from T80A 
and T80A blended with 5% (wt/wt) LWXFN in PBS and 10% FBS-RPMI. The release 
profiles from T80A in PBS and in 10% FBS-RPMI were used as controls, respectively. 
Asterisk indicates a significant difference, two-way ANOVA, P<0.05. All results are 
mean ± s.e.m, n = 3. 
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Figure 4.15A shows the interaction of PMX53 to 7 different nanoclays, Lucentite SWN (LSWN), 
Laponite BDS (LBDS), Lacontite SWN (LaSWN), Laponite OG (LOG), Laponite WXFP 
(LWXFP), Laponite WXFN (LWXFN) and Somasif ME100 (SME100). PMX53 was incubated 
with each nanoclay at 37oC in MilliQ H2O for 1 h. Nanoclays were separated by high speed 
centrifugation and supernatant was measured by LC-MS. The same treatment of PMX53 without 
nanoclays was used as control. Figure 4.15A shows that PMX53 was significantly bound to LSWN, 
LBDS, LaSWN, LOG, and LWXFP, and SME100 compared to control.  PMX53 had weak 
interaction to LWXFP and SME100 compared to LSWN, LBDS, LaSWN and LOG (Figure 4.15A). 
Longer time incubation might increase PMX53 adsorption to LWXFP and SME100. Therefore, to 
investigate the effect of nanoclays on the efflux of PMX53 from TPUs, we chose LSWN and 
LWXFN as model nanoclays, because PMX53 showed significant interaction with LSWN 
(student’s t-test, P<0.05,), but not with LWXFN (student’s t-test, P>0.05) (Figure 4.15A). 
 
Figure 4.15B shows the efflux of PMX53 from Tecoflex 80A (T80A) and Tecoflex 80A blended 
with 10% (wt/wt) LSWN. In this study, LSWN were dispersed in TPU solution by stirring and 
sonication. PMX53 was then added into the solution. Films were dried at room temperature, cut into 
1 cm x 1 cm, and then incubated at 37oC in MilliQ H2O. Compared to the efflux from T80A, the 
rate and extent of efflux from T80A blended with 10 % (wt/wt) LSWN were significantly decreased 
(Figure 4.15B).  
 
Figure 4.15C shows the efflux of PMX53 from T80A and T80A blended with 5% (wt/wt) LWXFN 
in different media. Compared with PMX53 released from T80A in PBS and 10% FBS-RPMI, the 
extent of PMX53 released from T80A blended with 5% (wt/wt) LWXFN in PBS and 10% FBS-
RPMI were significantly lower (Figure 4.15C). The concentration of PMX53 released from T80A 
blended with 5% (wt/wt) LWXFN approached equilibrium within 4 h (Figure 4.15C). Similar to the 
efflux from T80A, the amount released from T80A blended with 5% (wt/wt) LWXFN in the 
presence of serum was statistically higher than the release in PBS (Figure 4.15C). This increased 
release in the presence of serum may be due to the replacement of weakly bound PMX53 in the 
matrix by proteins. These results indicate that incorporating nanoclays into TPUs may hinder the 
diffusion of PMX53 from TPUs.  
 
4.2.12 In vitro release of other peptides from TPUs 
We also examined the relation between cumulative release and molecular weight of peptides. TPUs 
(5% wt/v in dichloromethane) were co-casted with the same amount of six different peptides (50 µg) 
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at room temperature. These peptides provide a range of molecular weight substrates (830 – 1500 
daltons). Peptide-loaded films were cut into 1 cm x 1 cm. The efflux was conducted by immersing 
films in PBS at 37oC. Table 4.1 shows the structures of SFT-1 and Xen2174. Compared to C5aR 
antagonists, these two peptides have larger molecular weight, and different biological targets. 
Figure 4.16 shows the mass spectrometry of Xen2174 and SFTI-1. Both peptides have 2 positive 
charges. The LC-MS analysis of Xen2174 and SFTI-1 is shown in Figure 4.17. Fragments 84.100 
Da of Xen2174 and fragment 70.200 Da of SFTI-1 were shown the highest intensity, and were used 
for further analysis.  
 
Figure 4.18A shows the release of peptides from Tecoflex 80A (T80A) at 72 h. There was a linear 
relationship between cumulative release at 72 h and molecular weight of peptides (y = -0.1060 x + 
157.0, R2 = 0.911) (Figure 4.18A). This result indicates that there was a negative correlation 
between cumulative release at 72 h and molecular weight of peptides. Figure 4.18B shows the 
release of peptides from ElastEon 5325 (E5325) at 72 h. Similar to the release from T80, the 
cumulative release from E5325 at 72 h decreased when increasing the molecular weight of peptides 
(Figure 4.18B). However, the goodness of fit R2 was 0.581. These results indicate that increasing 
the molecular weight of peptides may lead to decrease of drug released. In addition, the efflux of 
peptides from TPU films may also depend on the peptide 3D structure, which may affect the 
diffusion of peptides through the TPU films. 
 
   Table 4.1 Structures of SFT-1 and Xen2174. 
   Z : Glutamine or Glutamic acid, * : N-terminal amidation 
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Figure 4.16 Mass spectrometry of Xen2174 and SFTI-1. (A) Xen2174. 
Molecular weight (Mw) is 1403.0 Da. Scan was from 100 Da to 1420 Da.  
Xen2174 could be 1 ([Mw + H]+, 1404.3 Da) , 2 ([Mw + 2H]2+, 703.3 Da) or 4 
([Mw + 4H]4+, 376.4 Da) positively charged. Optimal ion mass was 2 positively 
charged (m/z= 703.3 Da). (B) SFTI-1. Mw is 1512.900 Da. Scan was from 500 Da 
to 1525 Da. SFTI-1 could be 1 ([Mw + H]+, 1514.2 Da) or 2 ([Mw + 2H]2+, 757.7 
Da) positively charged. Optimal ion mass was 2 positively charged (m/z= 757.7 
Da). 
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Figure 4.17 Representative LC-MS analysis of Xen2174 and SFTI-1. (A) Xen2174. 
Retention time was 6.68 min. Optimal product ion mass 84.100 Da of Xen2174 was 
used to analyse data. (B) SFTI-1. Retention time was 8.55 min. Optimal product ion 
mass 70.200 Da of SFTI-1 was used to analyse data. 
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Figure 4.18 In vitro release of other peptides from TPUs at 72 h. 
(A) Release of peptides from Tecoflex 80A. There was a linear 
relationship between cumulative release at 72 h and molecular weight 
of peptides. Linear regression y = -0.1060 x + 157.0, R2 = 0.911. (B) 
Release of peptides from ElastEon 5325. The cumulative release from 
E5325 at 72 h decreased when increasing the molecular weight of 
peptides, R2 = 0.581. 
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4.3 Discussion 
 
In this chapter, we have investigated the in vitro efflux of different peptides from TPUs. TPUs as 
drug delivery matrices have been widely studied. They have proven versatility for the delivery of 
therapeutics such as antimicrobial agents (Crisante, Francolini et al. 2009), anticancer drugs (Chen, 
Wang et al. 2011) and anti-inflammatory drugs (Da Silva, Ayres et al. 2009). TPUs can be 
synthesized from a variety of chemical building blocks, which enables structural flexibility for a 
range of biological applications. Biodegradable TPU scaffolds can produce long-term delivery of 
large proteins such as insulin-like growth factor (Nelson, Baraniak et al. 2011), bone morphogenic 
protein-2 (Li, Yoshii et al. 2009, Kim and Hollinger 2012) and platelet-derive growth factor (Li, 
Davidson et al. 2009). Li et al reported the controlled release of insulin from biodegradable 
poly(ether-urethane) hydrogels over 10 days (Li, Wang et al. 2014), while Wang et al recently 
showed that the peptide Bmap-28 could be released from the hydrophilic polyurethane PEGU25 
over more than 20 days (Wang, Liu et al. 2015). Both systems required a biodegradable matrix for 
delivery and therefore are designed as stand-alone delivery processes. By contrast, non-degradable 
TPUs are widely used in medical devices and implants because they are soft and flexible but still 
highly durable. This has been exploited for drug delivery by impregnating TPU-based implants such 
as catheters, coatings and dressings with different therapeutics. The advantage of this approach is 
theease of manufacture along with the multi-purpose use of the TPU device. However, there are 
very few studies on the release of peptides from different polyurethanes. Our studies suggest that it 
may be feasible to use TPUs as matrices to deliver peptides. 
 
We have specifically investigated the efflux of two C5aR antagonists (PMX53 and JPE1375) from 
TPUs. The different efflux profiles for both peptides from Tecoflex 80A (T80A) indicate that the 
chemical and physical structure of peptides may have a profound effect on the efflux (Figure 4.5A). 
However, neither of them showed significant release from ElastEon 5325 (E5325) (Figure 4.5A). 
The cause of this may be dependent on the composition of soft segments of polyurethanes. E5325 is 
comprised of a mixed macrodiol of α,ω-hydroxy-terminated polydimethylsiloxane (PDMS) as soft 
segment, which is highly hydrophobic (Osman, Andriani et al. 2012). E5325 has shown minimum 
water uptake compared to T80A (Figure 3.7B, Chapter 3), and there was no significant interaction 
of E5325 with either peptides (Figure 4.6). Similar efflux of model drugs from T80A and E5325 
were observed in previous work (Zhang, Martin et al. 2014). Therefore, this minimum water uptake 
may be the major factor that inhibits the diffusion of peptides through the TPU matrices. Other 
studies also show that the rate of drug release from polymeric matrices is positively correlated with 
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the rate of hydration (Fu and Kao 2010). As water diffuses into TPU films, it has at least 2 effects. 
Firstly, it solubilizes the crystalline drug embedded in the film allowing it to diffuse out of the 
polymer. Secondly, it hydrates the polymer backbone and induces swelling, which is primarily 
dependent on the soft segment composition (Green, Corneillie et al. 2000). 
 
On the basis of efflux of PMX53 from different TPUs (Figure 4.8), the urethane linkage (-NH-
COO-) in the hard segments of TPUs may form hydrogen bonding with peptide bonds (-NH-COO-). 
This hydrogen bonding may be similar to the beta sheet structure of proteins, in which the N-H 
groups in one strand form hydrogen bond with the C=O groups in the adjacent strands. Therefore, 
more urethane linkages in TPUs or more peptide bonds in peptides may lead to greater binding 
between TPUs and peptides, which result in the decreased rate or extent of efflux. Although not the 
purpose of this study, peptides with a different number of peptide bonds could be synthesized and 
released from TPU films to further ascertain this hypothesis. 
 
In the presence of serum, the efflux of PMX53 increased to about 100% over 3 days from T80A 
compared to the efflux in PBS and MilliQ H2O (Figure 4.9A). Bonferoni et al have shown the 
influence of buffer composition, pH and ionic strength on the release of drug from a polymer 
(Bonferoni, Rossi et al. 2000). The cause of this in my study may be due to the interaction between 
PMX53 and T80A. The distribution of PMX53 in T80A may involve two different compartments: 
one compartment contains free PMX53 that diffuses following hydration, and the other 
compartment contains immobilized PMX53. Proteins in the medium may penetrate into the TPU 
matrix and replace the weakly bound PMX53 in the matrix. This replacement may promote the 
efflux of PMX53.  
 
To control this rapid release in the presence of serum, we investigated the effect of blending T80A 
with E5325 on the efflux of peptides. With the aim of controlling the drug release, polyurethanes 
have been blended with different materials such as silk fibroin (Liu, Zhang et al. 2009) and chitosan 
(Sullad, Manjeshwar et al. 2015). The blended TPUs may exhibit different micro-domains because 
of incompatible of their hydrophilic hard and hydrophobic soft segments. The surface morphology 
and composition of blended TPUs may also be changed. These domains may affect the distribution 
of PMX53, hydration of matrix and flexibility of TPU chains, which would further affect the release 
profiles. The interaction between peptides and blended Tecoflex-ElastEon may involve two 
compartments: one compartment is the interaction of PMX53 with Tecoflex 80A, and the other 
compartment is the interaction of PMX53 with ElastEon 5325. The rate and extent of PMX53 
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released from T80A may be faster than from E5325. Therefore, the rate and extent of PMX53 efflux 
could be determined by modifying the concentration of E5325 in T80A (Figure 4.10A and B). The 
rate and extent of efflux may be suppressed by increasing the ratio of E5325 in T80A. These 
different release profiles from blended TPUs may be used for different drug delivery applications.  
 
In summary, we have been able to show that C5aR antagonists can be released in a controlled 
manner from polyurethane films in vitro without changing their in vitro bioactivity. However, 
solvent cast at mild conditions may limit the production of peptide-loaded polyurethanes, as low 
temperature may affect the physical property of TPU during film annealing and low boiling point of 
organic solvents may limit the solubility of TPU in solvents. We have been able to show that the 
release profiles could be controlled by the interaction of C5aR antagonists with the composition of 
hard and soft segments of TPUs. Blending Tecoflex with ElastEon might be a good approach for 
different peptides release applications. The stability of peptides in elevated temperature, organic 
solvent and serum medium can significantly affect their application in drug delivery.  
  
 
106 
 
 
4.4 Reference 
 
Boor, P. (2007). "Complement C5 mediates experimental tubulointerstitial fibrosis." J Am Soc 
Nephrol 18(5): 1508-1515. 
Bonferoni, M. C., S. Rossi, F. Ferrari, E. Stavik, A. Pena-Romero and C. Caramella (2000). 
"Factorial analysis of the influence of dissolution medium on drug release from 
carrageenan-diltiazem complexes." AAPS PharmSciTech 1(2): 72-79. 
Bruno, B. J., G. D. Miller, et al. (2013). "Basics and recent advances in peptide and protein drug 
delivery." Therapeutic Delivery 4(11): 1443-1467. 
Busolo, M. A., P. Fernandez, et al. (2010). "Novel silver-based nanoclay as an antimicrobial in 
polylactic acid food packaging coatings." Food Addit Contam Part A Chem Anal Control 
Expo Risk Assess 27(11): 1617-1626. 
Choy, J.-H., S.-J. Choi, et al. (2007). "Clay minerals and layered double hydroxides for novel 
biological applications." Applied Clay Science 36(1–3): 122-132. 
DeLeon, V. H., T. D. Nguyen, et al. (2012). "Polymer nanocomposites for improved drug delivery 
efficiency." Materials Chemistry and Physics 132(2-3): 409-415. 
Fonseca, M. I., R. R. Ager, et al. (2009). "Treatment with a C5aR antagonist decreases pathology 
and enhances behavioral performance in murine models of Alzheimer's disease." J Immunol 
183(2): 1375-1383. 
Fu, Y. and W. J. Kao (2010). "Drug release kinetics and transport mechanisms of non-degradable 
and degradable polymeric delivery systems." Expert Opin Drug Deliv 7(4): 429-444. 
Green, R. J., S. Corneillie, J. Davies, M. C. Davies, C. J. Roberts, E. Schacht, S. J. B. Tendler and P. 
M. Williams (2000). "Investigation of the hydration kinetics of novel poly(ethylene oxide) 
containing polyurethanes." Langmuir 16(6): 2744-2750. 
Gupta, S. (2013). "Oral delivery of therapeutic proteins and peptides: a review on recent 
developments." Drug Delivery 20(6): 237-246. 
Ha, J. U. and M. Xanthos (2011). "Drug release characteristics from nanoclay hybrids and their 
dispersions in organic polymers." Int J Pharm 414(1-2): 321-331. 
Li, B., J. M. Davidson and S. A. Guelcher (2009). "The effect of the local delivery of platelet-
derived growth factor from reactive two-component polyurethane scaffolds on the healing in 
rat skin excisional wounds." Biomaterials 30(20): 3486-3494. 
Li, B., T. Yoshii, A. E. Hafeman, J. S. Nyman, J. C. Wenke and S. A. Guelcher (2009). "The effects 
of rhBMP-2 released from biodegradable polyurethane/microsphere composite scaffolds on 
new bone formation in rat femora." Biomaterials 30(35): 6768-6779. 
Li, X., Y. Wang, J. Chen, Y. Wang, J. Ma and G. Wu (2014). "Controlled Release of Protein from 
Biodegradable Multi-sensitive Injectable Poly(ether-urethane) Hydrogel." ACS Applied 
Materials & Interfaces 6(5): 3640-3647. 
Liu, X.-Y., C.-C. Zhang, W.-L. Xu and C.-x. Ouyang (2009). "Controlled release of heparin from 
blended polyurethane and silk fibroin film." Materials Letters 63(2): 263-265. 
Morgan, M., A. C. Bulmer, et al. (2008). "Pharmacokinetics of a C5a receptor antagonist in the rat 
after different sites of enteral administration." European Journal of Pharmaceutical Sciences 
33(4): 390-398. 
Mortimer, G. M., N. J. Butcher, et al. (2014). "Cryptic epitopes of albumin determine mononuclear 
phagocyte system clearance of nanomaterials." ACS Nano 8(4): 3357-3366. 
Nitya, G., G. T. Nair, et al. (2012). "In vitro evaluation of electrospun PCL/nanoclay composite 
scaffold for bone tissue engineering." J Mater Sci Mater Med 23(7): 1749-1761. 
 
107 
 
Osman, A. F., Y. Andriani, et al. (2012). "Engineered nanofillers: impact on the morphology and 
properties of biomedical thermoplastic polyurethane nanocomposites." RSC Advances 2(24): 
9151-9164. 
Park, S., S. D. Kim, et al. (2014). "A novel delivery platform for therapeutic peptides." Biochemical 
and Biophysical Research Communications 450(1): 13. 
Pizzatto, L., A. Lizot, et al. (2009). "Synthesis and characterization of thermoplastic 
polyurethane/nanoclay composites." Materials Science and Engineering: C 29(2): 474-478. 
Proctor, L. M., T. M. Woodruff, et al. (2006). "Transdermal pharmacology of small molecule cyclic 
C5a antagonists." Adv Exp Med Biol 586: 329-345. 
Qu, H., D. Ricklin, et al. (2009). "Recent developments in low molecular weight complement 
inhibitors." Mol Immunol 47(2-3): 185-195. 
Schnatbaum, K., E. Locardi, et al. (2006). "Peptidomimetic C5a receptor antagonists with 
hydrophobic substitutions at the C-terminus: Increased receptor specificity and in vivo 
activity." Bioorganic & Medicinal Chemistry Letters 16(19): 5088-5092. 
Strachan, A. J., I. A. Shiels, et al. (2001). "Inhibition of immune‐complex mediated dermal 
inflammation in rats following either oral or topical administration of a small molecule C5a 
receptor antagonist." British Journal of Pharmacology 134(8): 1778-1786. 
Sullad, A., L. Manjeshwar and T. Aminabhavi (2015). "Blend microspheres of chitosan and 
polyurethane for controlled release of water-soluble antihypertensitive drugs." Polymer 
Bulletin 72(2): 265-280. 
Suresh, R., S. Borkar, et al. (2010). "Nanoclay drug delivery system." Int J Pharm Sci Nanotechnol 
3: 901-905. 
Wang, J., Q. Liu, Y. Tian, Z. Jian, H. Li and K. Wang (2015). "Biodegradable hydrophilic 
polyurethane PEGU25 loading antimicrobial peptide Bmap-28: a sustained-release 
membrane able to inhibit bacterial biofilm formation in vitro." Sci Rep 5: 8634. 
Woodruff, T. M., J. W. Crane, et al. (2006). "Therapeutic activity of C5a receptor antagonists in a 
rat model of neurodegeneration." FASEB J 20(9): 1407-1417. 
Zhang, J., D. J. Martin, et al. (2014). "Effect of supercritical carbon dioxide on the loading and 
release of model drugs from polyurethane films: comparison with solvent casting." 
Macromolecular Chemistry and Physics 215(1): 54-64. 
Zhang, X.-X., H. S. Eden, et al. (2012). "Peptides in cancer nanomedicine: drug carriers, targeting 
ligands and protease substrates." Journal of Controlled Release 159(1): 2-13. 
 
 
  
 
108 
 
 
Chapter 5 
 
Pharmacokinetics and pharmacodynamics of 
PMX53 released from polyurethane films 
using a mouse model 
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5.1 Introduction 
 
Previously, we have reported that therapeutic peptides were released from TPU films in a controlled 
manner by the interaction of peptides with hard and soft segments of TPU films. We have also 
shown that released peptides retained their bioactivity in vitro using U937 cells. In this chapter, we 
aimed to understand the pharmacokinetics and pharmacologic responses to PMX53 released from 
implanted TPU films using a mouse model.  
 
Specifically, we measured the plasma levels of PMX53 released from different TPU films and 
compared these to the plasma levels following intraperitoneal (i.p.) administration. Previous 
PMX53 studies have shown that PMX53 exhibits rapid elimination in rats (Strachan, Shiels et al. 
2001, Morgan, Bulmer et al. 2008). We, therefore, investigated whether the peptide delivery 
systems could prolong PMX53 plasma levels.  
 
We also examined whether the PMX53 released from TPU films retained its therapeutic effect by 
measuring B16-F10 melanoma tumor growth. Inflammation has been shown to play a dual role in 
both tumor promoting and antitumor effect (Grivennikov, Greten et al. 2010, Goldszmid, Dzutsev et 
al. 2014). Studies have shown that inflammation caused by implantation of biomaterials promoted 
cancer cells recruitment (Ko, Wu et al. 2012). Complement, a fundamental part of immune system 
and inflammation, has been recognised to contribute to cancer development (Pio, Ajona et al. 2013). 
The complement system initially provides a deleterious effect on cancer cells by generation of 
complement proteins (Weiner, Surana et al. 2010), which may recruit and activate immune cells to 
the tumor microenvironment (Dunkelberger and Song 2010). However, the surviving cancer cells 
could overexpress complement regulatory proteins to evade immunity (Rutkowski, Sughrue et al. 
2010). Among these complement regulatory proteins, C5a has been reported to be a key mediator in 
the regulation of cancer growth, such as lung cancer (Corrales, Ajona et al. 2012) and ovarian 
cancer (Nunez-Cruz, Gimotty et al. 2012). Blockade of C5a and C5aR binding by the C5aR 
antagonist, PMX53, has been shown to be an effective strategy in the modulation of antitumor 
immune response in animal models (Markiewski, DeAngelis et al. 2008). Their results for C5aR 
antagonist–treated mice suggested that C5 activation was required through complement activation 
and C5a was generated locally in the tumor microenvironment and subsequently contributed to 
mechanisms supporting tumor growth. Also, they have shown that the lower growth of tumors in 
C5aR-deficient mice might be most relevant to a C5a-mediated tumor-promoting activity of host 
cells (Markiewski, DeAngelis et al. 2008).  
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In this study, we hypothesised that the inflammation caused by implantation of TPUs might 
promote tumor growth, and PMX53 released from TPUs may diminish inflammation and impair 
tumor growth.  
 
5.2 Results 
 
5.2.1 In vitro release of PMX53 from blended Tecoflex and ElastEon disks 
In Chapter 4, we cut peptide-loaded films into 1 cm x 1 cm for release studies. In this chapter, to 
easily insert a peptide-loaded film into the mouse peritoneum cavity, we cast peptide-loaded films 
into disks (the diameter was about 1 cm) by dissolving TPUs in dichloromethane (5% wt/v) and co-
casting with PMX53 (3 µg) into an 18-well Teflon plate. PMX53 was used for in vivo studies due to  
 
 
Figure 5.1 Efflux of PMX53 from blended TPU disks. Efflux 
was conduct at 37oC in 10% FBS-RPMI over 48 h. The efflux from 
T80A was compared to from 50% T80A and E5325. The efflux 
from 5% T80 was compared to from E5325. Asterisk indicates a 
significant difference, two-way ANOVA, P<0.05. All results are 
mean ± s.e.m, n = 3.  
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the stability of PMX53 in the presence of serum. Before any in vivo pharmacokinetics study were 
performed, we investigated the in vitro release of PMX53 from TPU disks at 37oC in 10 % FBS-
RPMI over 48 h. All the samples were measured by LC-MS against a standard curve prepared in 10% 
FBS-RPMI. 
 
Figure 5.1 shows the in vitro efflux of PMX53 from disks. Similar to the release profiles from 
square films (1 cm x 1 cm) (Figure 4.10, Chapter 4), the efflux rate and extent of PMX53 from 
disks were significantly suppressed by increasing the amount of ElastEon 5325 (E5325) in Tecoflex 
80A (T80A) (Figure 5.1). The efflux from T80 approached about 100% cumulative release in 10% 
FBS-RPMI within 48 h (Figure 5.1). The rate and extent of release from T80 were statistically 
higher than from other blended TPU disks (two-way ANOVA, P<0.05) (Figure 5.1), and there was 
minimum efflux (about 10%) of PMX53 from E5325 disks (Figure 5.1). Compared to efflux from 
E5325, there was no significant difference from 5% T80A (two-way ANOVA, P>0.05,). This result 
indicates that similar to the efflux from square films, the blending of T80A and E5325 could also 
control the efflux of PMX53 from disks. For further in vivo study, we primarily investigated the 
pharmacokinetics of PMX53 from the T80A disks and blended 50% T80A disks.  
 
5.2.2 In vivo intraperitoneal injection (i.p.) of PMX53 
Figure 5.2A shows the standard curve of PMX53 in 100% FBS prepared in the same way as all the 
samples. Formula y = 3.111x was used to analyse data, and R2 = 0.99. A representative spectrum of 
PMX53 using JPE1375 as internal standard is shown in Figure 5.2C.  
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Figure 5.2 In vivo i.p. injection of PMX53. (A) Standard curve of PMX53 in serum, 
linear regression y = 3.111 x, R2 = 0.99. Standard curves were prepared in serum using the 
same protocol as plasma samples. Results are mean ± s.e.m, n = 3. (B) The plasma levels 
of PMX53 following i.p. injection. Each mouse was injected intraperitoneally (i.p.) with a 
single dose of 1 mg/kg PMX53 (50 µl). Results were analysed using one phase decay 
model. Results are mean ± s.e.m, n = 4. (C) Representative spectrum of PMX53 using 
JPE1375 as internal standard. Optimal product ion mass 70.100 Da of PMX53 (896.3 Da) 
and 197.300 Da of JPE1375 (955.5 Da) was used to analyse data. 
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Figure 5.2B shows the PMX53 plasma levels following i.p. injection. The PMX53 plasma level 
increased to about 900 ng/ml within 5 min, and the elimination of PMX53 in plasma was very rapid 
(Figure 5.2B). The following empirical equation (one phase decay model, GraphPad Prism, Version 
6.0) was fitted to the data (Dinkelaar, Molenaar et al. 2013): 
 
                                                𝑌 = 𝑌0 ∙ 𝑒
−𝑘 ∙ 𝑋                                             (4) 
 
where 𝑌 is the concentration of PMX53 in plasma level at time 𝑋,  𝑌0 is the estimated maximum 
concentration of drug in plasma level. Because of the very rapid absorption of PMX53, plasma 
kinetics were analysed assuming no absorption phase. Pharmacokinetic parameters are listed in 
Table 5.1. Constant 𝑘  is the elimination rate. The half-life (t1/2) was calculated as 0.693/𝑘 . 
Clearance (𝐶𝑙) was calculated as 𝐶𝑙 =
𝐷𝑜𝑠𝑒
[𝐴𝑈𝐶]
; volume of distribution was calculated as: 𝑉𝑑 =
𝐷𝑜𝑠𝑒
𝑘[𝐴𝑈𝐶]
.  
 
Table 5.1 Pharmacokinetic parameters for i.p. injected PMX53 
Drug 
AUC 
(ng h/ml) 
t1/2 (h) 𝐶𝑙 (ml/h) Vd (ml) 𝑘 (h-1) 
PMX53 176.8 0.17 113.12 27.73 4.08 
AUC: area under the PMX53 plasma curve; t1/2: half-life of PMX53; 𝐶𝑙: clearance; Vd: volume of 
distribution; 𝑘: the elimination rate constant. 
 
These results show that the adsorption and elimination of PMX53 were rapid following i.p. 
injection.  
 
5.2.3 In vivo pharmacokinetics of PMX53 released from TPUs 
We next investigated the in vivo pharmacokinetics of PMX53 released from Tecoflex 80A (T80A) 
and blended 50% Tecoflex 80A-50% ElastEon 5325 (50% T80).  Male C57BL/6 mice were 
anesthetized with isoflurane in oxygen. A small incision was made in the abdomen. T80A and 50% 
T80A containing 200 µg of peptide PMX53 were implanted into the peritoneal cavity, respectively. 
The incision was sutured and cleaned. The animals were allowed to recover from anaesthesia. 
Blood samples were collected into heparinized tubes by cardiac puncture at each time point and 
treated as described above.  
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The plasma level of PMX53 released from T80A was monitored for 24 h as shown in Figure 5.3A. 
The following equation (one-compartment model with first-order absorption and elimination) was 
fitted to the data (Yamaoka, Nakagawa et al. 1978):  
 
                                              𝑦 =  
𝐷𝑜𝑠𝑒 ∙ 𝑘𝑎
𝑉𝑑 ∙ (𝑘𝑎−𝑘𝑒)
(𝑒−𝑘𝑒 ∙ 𝑥 − 𝑒−𝑘𝑎 ∙ 𝑥)                                (5) 
 
where 𝑦  is the concentration of PMX53 in plasma level at time 𝑥,  𝑉𝑑  is the volume of 
distribution, 𝑘𝑎 is the absorption rate constant and 𝑘𝑒 is the elimination rate constant. The half-life 
(t1/2) was calculated as 0.693/𝑘𝑒. The pharmacokinetic parameters for the efflux of PMX53 from 
T80A are displayed in Table 5.2. Compared to i.p. injected PMX53 with half-life about 0.17 h 
(Figure 5.2B), the half-life of PMX53 released from T80A extended to 0.98 h. This result indicates 
that PMX53-loaded T80A could extend the half-life of PMX53 compared to i.p. injection. 
 
 
 
Table 5.2 Pharmacokinetic parameters for the efflux of PMX53 from T80A and from 50% 
T80A 
TPU 
AUC 
(ng h/ml) 
t1/2 (h) 
Vd 
(ml) 
𝑘𝑎 𝑘𝑒 𝑘0 𝑇𝑑 
T80A 906.6 0.98 411.8 0.323 0.704 - - 
50% 
T80A 
5441 0.98 
V1 =275.1 
V2 =32.99 
0.788 0.704 615.7 0.292 
AUC: area under the curve; t1/2: half-life; Vd: volume of distribution; 𝑘𝑎: absorption rate constant; 
𝑘𝑒: elimination rate constant; 𝑘0: infusion rate; 𝑇𝑑: lag of time. 
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Figure 5.3B shows the plasma levels of PMX53 released from 50% T80A. The highest plasma level 
was about 125 ng/ml at 2.5 h released from T80A (Figure 5.3A), while the highest plasma level 
from 50% T80A was lower than from T80A and shifted to 1.5 h (Figure 5.3B). The plasma level of 
PMX53 was detectable over 9 days from 50% T80A (Figure 5.3B). 
 
On the basis of the outcomes of modeling the i.p. injection and release of T80A, we can predict the 
in vivo fate of PMX53 from 50% T80A. The following equation was fitted to the data of PMX53 
released from 50% T80A: combined one-compartment model with first-order elimination and 
infusion, which assumes the slow release of PMX53 is equivalent to a constant infusion: 
 
               𝑦 =  
𝐷𝑜𝑠𝑒 ∙ 𝑘𝑎
𝑉1 ∙ (𝑘𝑎−𝑘𝑒)
(𝑒−𝑘𝑒 ∙ 𝑥 − 𝑒−𝑘𝑎 ∙ 𝑥) +
𝑘0
𝑉2 ∙ 𝑘𝑒
(1 − 𝑒−𝑘𝑒(𝑥−𝑇𝑑))                        (6) 
 
where 𝑘0 is infusion rate, determined by the slow rate of efflux from 50% T80A after lag time 
(Figure 5.3D). 𝑇𝑑 is lag time. For 50% T80A, 𝑘𝑒 was assumed to be equal to the 𝑘𝑒 in modeling 
release of T80A. V1 is the volume of distribution in the first rapid release process, V2 is the volume 
of distribution in the second slower process. Goodness of fit was determined by using coefficient of 
determination (R2 = 0.7442). The outcomes of modeling the release of PMX53 from 50% T80A are 
summarized in Table 5.2.  
 
Compared to the monophasic and rapid release from T80A, the plasma levels of PMX53 released 
from 50% T80A were best described by equation 6 above indicative of 2 processes, an initial rapid 
release process (one compartment with first-order elimination) and a slower process with a lag of 
0.292 h (infusion). The volume of distribution was different in these 2 processes (V1, V2). For the 
same dose implantation, AUC of PMX53 released from 50% T80A (5441 ng h/ml) was higher than 
AUC of PMX53 released from T80A (906.7 ng h/ml). This may be due to the increased retention of 
PMX53 in the systemic circulation by 50% T80A. The absorption rate constant for PMX53 released 
from 50% T80A (𝑘𝑎 = 0.788) was higher than from T80A (𝑘𝑎 = 0.323), which indicates that more 
fraction of PMX53 released from 50% T80A reached to the systemic circulation. 
 
To determine the amount of PMX53 remaining in the films after in vivo efflux, implanted films 
were collected and washed in MilliQ H2O. Films were dried with filter paper before immersing in 
ethanol (1 ml), which was used to swell films and dissolve unreleased PMX53.  The amount of 
PMX53 remaining in the films was measured using LC-MS.  
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Figure 5.3C and D illustrate the amount of PMX53 released from T80A and 50% T80A in vivo, 
respectively. The efflux from T80A approached about 55% over 24 h (Figure 5.3C). Compared to 
the efflux from T80A, the rate and extent of efflux from 50% T80A was statistically lower over 24 
h (two-way ANOVA, P<0.05) (Figure 5.3C). Figure 5.3D shows the amount of PMX53 released 
from 50% T80A over 9 days. The first release process accounted for approximately 25% of the total 
drug efflux (Figure 5.3D). The efflux approached about 100% cumulative release on day 9 (Figure 
5.3D). Therefore, for PMX53 released from 50% T80A, there was no further measurement of 
plasma level after 9 days. The release profile in Figure 5.3D further confirmed the 2 process release 
from 50% T80A. These results indicate that similar to in vitro studies (Figure 4.10, Chapter 4), the 
initial rate and extent of drug release in vivo was significantly suppressed by blending T80A with 
E5325 (Figure 5.3C). The rate and extent of drug release in vivo from blended TPUs were 
dependent on the composition of the hard and soft segments (Figure 5.3C). 
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Figure 5.3 PMX53 plasma levels following administrated by implantation of 
PMX53-loaded TPUs into the mice peritoneal cavity. (A) PMX53 plasma levels 
following implantation of PMX53-loaded (200 µg) T80A into the peritoneal cavity. 
Plasma samples were collected by cardiac puncture. JPE1375 were used as internal 
standard. One compartment model (equation 5) was fitted to the data. Results are mean ± 
s.e.m, n =3. (B) PMX53 plasma levels following implantation of PMX53-loaded (200 
µg) 50% T80A into the peritoneal cavity. Equation 6 was fitted to the data. Results are 
mean ± s.e.m, n =3. (C) The in vivo release of PMX53 from T80A and 50% T80A over 
24 h determined by measuring the amount of PMX53 remaining in the films. Asterisk 
indicates a significant difference, two-way ANOVA, P<0.05. Results are mean ± s.e.m, n 
= 3. (D) The in vivo release of PMX53 from 50% T80A over 9 days. Results are mean ± 
s.e.m, n =3. 
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5.2.4 In vivo plasma levels of PMX53 released from TPUs loaded with different doses 
To investigate if there was a relationship between the loading doses and plasma levels at a particular 
time point, we cast blended 50% Teocflex 80A-50% ElastEon 5325 (50% T80A) with different 
doses of PMX53 (100 µg, 200 µg, 500 µg and 1000 µg, respectively). PMX53-loaded films were 
implanted into the peritoneal cavity. Blood samples were collected at 24 h by cardiac puncture after 
films implantation.  
 
Figure 5.4A shows the resulting plasma levels of PMX53. The result indicates that there was a 
significant linear correlation between PMX53 plasma level and the amount of drug loading (R2 = 
0.7448). Linear regression y = 0.05094 x + 10.03 (Red dashed line in Figure 5.4A). Data were 
analysed by GraphPad Prism, Version 6.0.  
 
  
 
 
Figure 5.4 Plasma levels of PMX53 released from 50% T80A with different 
loading doses. (A) Plasma levels of PMX53 released from 50% T80A loaded with 
different doses at 24 h. JPE1375 were added into each plasma sample as internal 
standard. Data were analysed by linear regression (GraphPad Prism, Version 6.0).  y = 
0.05094 x + 10.03 (Red dash line), R2 = 0.7448. Results are mean ± s.e.m, n =3. (B) 
The in vivo relationship between the cumulative release and drug loading doses at 24 h, 
determined by measuring the amount of PMX53 remaining in the films after in vivo 
release. Results are mean ± s.e.m, n =3. There was no significant difference compared 
the cumulative release of different drug loading doses (one-way ANOVA, Brown-
Forsythe test, P>0.05). 
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To determine the amount of PMX53 remaining in the films after 24 h, implanted films were 
collected and immersed in ethanol (1ml), and measured using LC-MS. The cumulative release of 
different loading doses was similar (one-way ANOVA, Brown-Forsythe test, P>0.05) (Figure 5.4B). 
This result indicates that increasing the drug loading doses may increase the PMX53 plasma levels 
in a linear fashion. 
 
5.2.5 The concentration of PMX53 in liver tissue after implantation of TPUs  
To further understand the in vivo fate of PMX53, we examined the concentration of PMX53 in liver 
tissue after implantation of TPUs. PMX53-loaded (200 µg) TPU films were implanted into the 
peritoneal cavity. Liver tissues (around 50 mg) were collected at each time point into cold MilliQ 
H2O (500 µl). Due to the instability of JPE1375 in the presence of enzymes and sonication process, 
PMX205 was added into each sample as internal standard. PMX53 was extracted from liver tissue 
by sonication. Acetonitrile with 1% formic acid was added into each sample (volume ratio of 3:1) to 
precipitate proteins before centrifugation. Supernatants (1.8 ml) were collected and freeze-dried. 
Samples were re-dissolved in methanol (100 µl) and measured by LC-MS. The standard curve 
samples were prepared using livers from untreated animals following the same protocol.  
 
A representative spectrum of PMX53 using PMX205 as internal standard is shown in Figure 5.5C. 
PMX53 was eluted from the column at 6.92 min, while PMX205 was at 7.09 min. Optimal ion mass 
896.3 Da of PMX53 and fragment 70.1 Da of PMX205 were used to analyse data. Figure 5.5A 
shows the standard curve for PMX53 prepared using livers from untreated mice. Peak area ratio was 
determined by the peak area of PMX53 (ion mass 896.3 Da) dividing by the peak area of PMX205 
(fragment 70.1 Da). Formula y=4.167 x was used to analyse the data, and R2 is 0.992.  
 
Figure 5.5B shows the concentration of PMX53 in liver tissue following administrated by 
implantation of TPUs. At 24 h, there was a significant difference in the concentration of PMX53 in 
liver tissue between mice implanted with 50% T80A and mice implanted with T80A (Student’s t-
test, P<0.05) (Figure 5.5B). For mice implanted with 50% T80A, the concentration of PMX53 in 
liver tissue was measurable over 9 days and exhibited a two-phase process, an initial increase over 3 
days and a decrease from day 3 to day 9 (Figure 5.5B). The amount of PMX53 in liver from mice 
implanted with 50% T80A was lower than the amount of PMX53 in plasma (Figure 5.3B and 
Figure 5.5B). The concentration of PMX53 measured in liver tissue may be due to the blood residue 
in liver tissue. 
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Figure 5.5 The concentration of PMX53 in liver tissue following administrated by 
implantation of TPUs. (A) Standard curve of PMX53 in liver solution. Standard 
PMX53 were added into cold MilliQ H2O (500 µl) containing blank livers (around 50 
mg) from untreated mice. PMX205 was used as internal standard. Results are mean ± 
s.e.m, n = 2. (B) The concentration of PMX53 in liver tissue following administrated by 
implantation of TPUs. Asterisk indicates a significant difference, Student’s t-test, 
P<0.05. Results are mean ± s.e.m, n = 2. (C) Representative spectrum of PMX53 using 
PMX205 as internal standard. Optimal ion mass 896.3 Da of PMX53 and fragment 70.1 
Da of PMX205 (839.5 Da) was used to analyse data. 
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5.2.6 Effect of PMX53 released from TPUs on the B16-F10 melanoma tumor growth 
Studies have demonstrated that repetitive injection of PMX53 could impair tumor growth due to the 
role of complement system in cancer proliferation (Lambris, Benencia et al. 2008, Corrales, Ajona 
et al. 2012, Nunez-Cruz, Gimotty et al. 2012). Therefore, we examined whether the PMX53 
released from TPUs retained its bioactivity by studying the effect on the B16-F10 melanoma tumor 
growth. 
 
 
 
 
Figure 5.6 Expression of C5aR in B16-F10 and Raw 264.7 cells. (A) C5aR expression 
in B16-F10 and Raw 264.7 cells. Total RNA was extracted from cells and C5aR mRNA 
levels were quantified by real-time PCR. Compared to Raw 264.7, the expression of 
C5aR in B16-F10 was statistically different. The asterisk denotes a significant difference 
(Student’s t-test, P<0.05). Results are presented as the mean ± S.E.M., n = 3. (B) PCR gel 
of C5aR expression. Results are presented as the mean ± S.E.M., n = 2. 
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Figure 5.7 Effect of PMX53 released from TPUs on B16-F10 melanoma tumor 
growth. (A) Tumor growth of mice implanted with blank 50% T80A films or PMX53-
loaded 50% T80A. Mice were injected subcutaneously with B16-F10 melanoma cells 
(200,000) in the rear right flank. On the fourth day after cells injection, mice were 
implanted with blank 50% T80A films or PMX53-loaded (200 µg) films. At day 6 after 
cells injection, tumor size was measured by caliper every day until mice were sacrificed. 
Control group is mice implanted with blank 50% T80A films. The asterisk denotes a 
significant difference compared to the control group (two-way ANOVA, P<0.05). 
Results are mean ± s.e.m, n = 6. (B) Survival curves of mice implanted with blank 50% 
T80A films or PMX53-loaded (200 µg) 50% T80A. Mice implanted with PMX53-loaded 
films were compared to mice implanted with blank films (log-rank test, P<0.05). Results 
are mean ± s.e.m, n = 6. (C) Body weight of wild-type C57BL/6 mice implanted with 
blank 50% T80A films or PMX53-loaded (200 µg) 50% T80A. Results are mean ± s.e.m, 
n = 6. 
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Firstly, we investigated C5aR expression on B16-F10 melanoma cells. RNA was extracted from 
cells using RNeasy Mini kit according to the manufacturer’s protocol for synthesizing cDNA. For 
expression levels of C5aR mRNA in B16-F10 cells and Raw 264.7 cells, real time PCR was used. 
Raw 264.7 cells were used as positive control, and β–actin was used as an internal control. Figure 
5.6A shows the relative expression of C5aR in B16-F10 and Raw 264.7 cells. Compared to Raw 
264.7, melanoma cells B16-F10 expressed much less C5aR mRNA (Figure 5.6). The expression of 
C5aR was also examined by gel electrophoresis (Figure 5.6B). The intensity of C5aR in B16-F10 
was much lower than in Raw 264.7. 
 
We next evaluated B16-F10 melanoma tumor growth in wild-type C57BL/6 mice implanted with 
blank 50% Tecoflex 80A-50% ElastEon 5325 (50% T80A) films or films containing PMX53 (200 
µg). B16-F10 cells were grown in complete medium in vitro, and then were trypsinised and 
resuspended in PBS. Each mouse was injected subcutaneously with B16-F10 melanoma cells 
(200,000) in the rear right flank. Mice body weight was monitored every day after cells injection. 
On the fourth day, mice were anaesthetised and implanted with blank 50% T80A films or films 
containing PMX53 (200 µg). Mice were allowed to recover from the surgery. At day 6 after cells 
injection, mice were anesthetized and their tumor size was measured by caliper every day until the 
tumor size reached 800 mm3, at which time mice were sacrificed.  
 
Figure 5.7A illustrates the tumor growth in mice implanted with blank 50% T80A films or PMX53-
loaded films. Compared to the control group, tumor in mice implanted with PMX53-loaded films 
grew slower (two-way ANOVA, P<0.05) (Figure 5.7A). Figure 5.7B shows the survival of mice in 
each group. Mice implanted with PMX53-loaded films were sacrificed during 15-17 days (Figure 
5.7B). Compared to the group implanted with blank 50% T80A sacrificed during 13-15 days, mice 
implanted with PMX53-loaded films had significant longer survival time (Kaplan-Meier Survival 
curve, Log-rank test, P<0.05) (Figure 5.7B). These results show that PMX53 released from 50% 
T80A retains its bioactivity, impairs tumor growth and prolongs the survival time. There was no 
significant difference in body weight observed in any of the groups (Figure 5.7C), indicating that 
there is no over toxicity associated with implantation surgery and tumor injection. Slight weight 
decrease (red arrow) on the surgery day may result from the recovery from surgery (Figure 5.7C).  
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5.3 Discussion 
 
In this study, we have shown that single dose i.p. injection of PMX53 exhibited rapid rate of 
adsorption and elimination. PMX53 studies have shown that it is rapidly eliminated in rat after oral 
administration (Strachan, Shiels et al. 2001, Morgan, Bulmer et al. 2008) and in mice after 
subcutaneous administration (Benson, Thomas et al. 2015). The result of single dose PMX53 i.p. 
injection in this chapter corresponds to previous PMX53 studies (Strachan, Shiels et al. 2001). To 
prolong the PMX53 plasma levels and enhance the therapeutic effect, using drug delivery systems 
may be an effective strategy. Studies have shown that it is feasible to use drug delivery systems to 
prolong the therapeutic effect of small molecule drugs (Dang, Bratlie et al. 2011, Chen, Huang et al. 
2012). Therefore, it is important to determine whether the drug delivery system we developed could 
prolong the peptide PMX53 plasma level and therapeutic effect in vivo. 
 
We first examined the plasma levels of PMX53 released from Tecoflex 80A and blended 50% 
Tecoflex 80A-50% ElastEon 5325 (50% T80A) using a mouse model. When PMX53-loaded films 
were implanted into the peritoneal cavity, drug was released from films in a controlled manner. 
PMX53 released from TPU films may interact with cells in the peritoneal cavity, and a fraction of 
released PMX53 was adsorbed into systemic circulation. PMX53 was distributed to organs and 
tissue, metabolised or excreted (Shargel, Wu-Pong et al. 2007).  
 
For T80A, the release kinetics was fitted by one-compartment model with first-order elimination. 
The initial rate of release was rapid, which results in the rapid increase of plasma level of PMX53 
over 2.5 h. Then the rate of release decreased to a value, which was probably lower than the 
elimination rate. In this case, elimination will be the major cause of the decrease of PMX53 plasma 
level. 
 
For 50% T80A, efflux occurred from 2 kinetically distinct compartments (Figure 5.3B). Release 
over the early time points was fast and followed one-compartment model with first-order 
elimination. In the second compartment, release after the lag time was slower and mimicked an 
infusion. The cause of this may be due to the interaction of PMX53 with C5aR on tissue cells. In 
the first compartment, the decrease of PMX53 plasma level may be not only due to elimination, but 
also to the binding with C5aR on tissue cells. These receptors represent a significant compartment 
because PMX53 associated with such high affinity. PMX53 may be distributed to all tissues in the 
body, which result in the large volume of distribution (V1). In the second compartment, because of 
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the saturation of binding between PMX53 and C5aR on tissue cells over the first process, PMX53 
released from 50% T80A was distributed to systemic circulation, which results in the small volume 
of distribution (V2). The rate of release from 50% T80A in the second stage may be equal to the rate 
of elimination, which leads to the equilibrium of PMX53 plasma level over 9 days.  
 
Compared to the absorption rate of PMX53 from T80A (𝑘𝑎= 0.323), the adsorption rate of PMX53 
from 50% T80A was higher (𝑘𝑎= 0.788). The cause of this may be due to the rate and extent of 
PMX53 released from TPU films. The rate and extent of efflux has been shown to be dependent on 
the composition of hard and soft segments in TPUs. Therefore, the interaction of PMX53 with soft 
and hard segments of TPUs may contribute to the adsorption rate and further affect in vivo 
pharmacokinetics. PMX53 released from 50% T80A was significantly slower and had longer 
duration in plasma level (Figure 5.3B and C). This slow release from 50% T80A may enhance the 
adsorption of PMX53 and maintain the concentration within an acceptable therapeutic range over a 
long period of time, which may improve the efficacy of PMX53. 
 
Previous work has demonstrated that tumour growth is enhanced by an inflammatory environment 
(Vakkila and Lotze 2004) and that anti-inflammatory drugs decrease the risk of certain cancers such 
as gastric, colon and breast (Gonzalez-Perez, Garcia Rodriguez et al. 2003, Wang, Huang et al. 
2003). In addition, PMX53 has been shown to affect ovarian cancer proliferation by inhibiting 
neovascularization (Nunez-Cruz, Gimotty et al. 2012). To investigate if the released PMX53 
maintains its bioactivity in vivo, we compared the tumor growth of mice implanted with blank 50% 
T80A films and PMX53-loaded 50% T80A films. Repetitive injection of PMX53 has been shown 
to impair cervical tumor growth (Markiewski, DeAngelis et al. 2008). We have shown that PMX53 
released from 50% T80A significantly impaired B16-F10 melanoma growth compared to the 
control group (Figure 5.7). Therefore, PMX53 released from 50% T80A retained its bioactivity in 
vivo and single dose implantation of PMX53-loaded films prolonged the therapeutic effect. 
However, the underlying mechanisms for the role of PMX53 in the melanoma tumor growth have 
remained elusive. C5aR expressed on melanoma cells B16-F10 was significant less than on 
macrophage Raw 264.7 cells (Figure 5.6). The reason why C5aR antagonist PMX53 impaired 
tumor growth may be dependent on the interaction of PMX53 with immune cells, and not a direct 
interaction with the tumor cells. In the tumor microenvironment, local concentration of C5a is 
critical in determining its role in tumor progression (Gunn, Yan et al. 2012). The interaction of C5a 
with C5aR was shown to recruit more myeloid-derived suppressor cells, enhance the generation of 
key immunosuppressive molecules and suppress immune cell-mediated antitumor responses 
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(Markiewski, DeAngelis et al. 2008). Blockade of C5aR signalling by PMX53 was reported to 
down-regulate the expression of these key immunosuppressive molecules, promote the T cells 
infiltration and further  activate antitumor immune responses to impair the tumor growth (Pio, 
Ajona et al. 2013). In this study, PMX53 released from TPU films may inhibit the interaction of 
C5a with C5aR on immune cells in the tumor microenvironment. This inhibition may promote 
antitumor immune responses to suppress the B16-F10 melanoma growth by down-regulating the 
expression of some key immunosuppressive molecules.   
 
In summary, we have shown that the drug delivery systems we developed were able to prolong the 
plasma level of PMX53 and the PMX53 released from TPU films retained biological activity. The 
efflux rate and extent from TPUs films, determined by the interaction of PMX53 with hard and soft 
segments of TPU films, contributed to the physiological pharmacokinetics and pharmacodynamics 
of PMX53. These drug delivery systems may provide significant value for future clinical 
application. 
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Chapter 6  
General Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
Novel drug discovery and development can be time and money consuming. Improving efficacy and 
safety of existing drugs using different methods of administration have been widely investigated 
and can overcome the cost of new drug discoveries in some circumstances. Although current 
clinical therapies based on oral, intravenous and subcutaneous administration have played important 
role in the treatment of diseases, polymer-based drug delivery systems promise much in treatment 
of diseases with superior control of delivery and efficiency (Liechty, Kryscio et al. 2010). Many 
different biomaterials have been implanted for the treatment of various diseases such as hearing loss 
(Wilson and Dorman 2008), cardiac dysfunction (Lam 2012), and bone regeneration (Stevens 2008). 
Drug delivery systems using biomaterials as carriers have gained considerable popularity due to 
many favorable biological properties. Thermoplastic polyurethanes (TPUs) as a special class of 
biomaterials are widely used for implantable devices. Here, we have shown that TPUs may be ideal 
for controlled release of therapeutic peptides. 
 
In a brief summary, this project investigated the capability of thermoplastic polyurethanes to deliver 
therapeutic peptides, such as C5aR antagonists, and the efficacy of the peptide delivery systems. 
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Firstly, we compared the effect of supercritical carbon dioxide treatment and solvent casting on the 
loading and release of model drugs from TPU films. The effect of supercritical carbon dioxide 
treatment on the physical and mechanical properties was examined. Owning to the low loading 
capacity of the supercritical carbon dioxide technique, we then investigated the in vitro release of 
peptides from TPU films mainly by solvent casting. This project demonstrated that the peptide-
loaded TPU delivery systems were able to control the release of peptides and retain their bioactivity 
both in vitro and in vivo.  
 
6.1 Effect of supercritical carbon dioxide on the loading and release of model drugs 
from polyurethane films: comparison with solvent casting 
Supercritical fluid technique has been widely used for preparation of drug delivery systems, 
including encapsulation of drugs within polymer (Ginty, Barry et al. 2008) and impregnation of 
drugs into polymer films (Hussain and Grant 2012). However, many therapeutic agents have a very 
low solubility in scCO2, except for small molecule drugs. Despite this drawback, this approach has 
already been used to fabricate polymeric microparticles that encapsulate bioactive proteins 
(Whitaker, Hao et al. 2005).  
 
In this study, we compared the effect of supercritical carbon dioxide treatment and solvent casting 
on the loading and release of model drugs from polyurethane films (Chapter 3). Drug-loaded 
polyurethane films were prepared by employing supercritical carbon dioxide as a solvent carrier 
medium, which could dissolve model drugs, swell TPU films and loaded dissolved drugs into TPU 
films. The main reasons we used this technique were to provide mild conditions for further study of 
bioactive peptides and avoid the use of organic solvents to maintain the stability of peptides. We 
examined the effect of supercritical carbon dioxide on the physical and mechanical properties of 
TPUs. Importantly, this study provides much needed information on drug loading using 
supercritical carbon dioxide compared to solvent casting.  
 
There are several interesting findings that are worth noting. Firstly, we have shown that scCO2 
treatment of TPUs does not significantly affect their physical and mechanical properties. However, 
some reorganization of TPU near the surface at a microscopic level was induced by scCO2 
treatment and was exacerbated in PBS. Reorganization of TPU in aqueous solution has been 
previously reported (Xu, Runt et al. 2010). We found scCO2 treatment may exacerbate the 
reorganization. To determine whether these changes affect the application of TPU as drug carriers, 
we examined the loading of 3 model drugs using scCO2 and compared these to using solvent 
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casting. Results have shown that all these 3 model drugs were loaded consistently and 
homogeneously into films by scCO2 (Chapter 3), indicating feasibility of the technique. However, 
when we increased the total amount of drug in the scCO2 apparatus, the amount of rhodamine B and 
fluorescein loaded into the films approached equilibrium. Compared to solvent casting, this low 
loading efficiency by scCO2 may be related to the nature of drugs, such as the solubility of drugs in 
scCO2, the structure of drugs and the hydrophobicity of drugs (Kalani and Yunus 2011). For 
instance, lipophilic drugs have been shown to be difficult to load into polymer by scCO2 (Yeo and 
Kiran 2005). This approach shows the limitation for application to expensive therapeutics due to the 
low solubility of therapeutic compounds, such as peptides or proteins, in scCO2.  
 
The rearrangement near the surface may contribute to the efflux of therapeutic drugs. The efflux of 
rhodamine B and fluorescein exhibited biphasic release (Figure 3.5, Chapter 3). This may be 
associated with the re-arrangement of hard segments to the surface of the film. To design drug 
delivery systems, drugs could be engineered to interact with the hard segments of TPU. The efflux 
of drugs could then be controlled by the re-arrangement of hard segments to the surface of the film. 
 
We also examined the release of rhodamine B from TPUs with different hard and soft segments. The 
efflux profiles may be dependent on the chemical structure of the drug, the composition of hard and 
soft segments of polyurethanes, and microphase rearrangement of the hard segments to the surface 
of the film during CO2-annealing. These findings provide important information for designing 
appropriate drug delivery systems. However, due to the low loading capacity of scCO2 technique, 
we loaded peptides into TPU films by solvent casting for further studies. 
 
6.2 In vitro controlled release of therapeutic peptides from polyurethane films 
Based on the chapter 3 results, we next investigated the in vitro release of peptides from TPU films. 
There have been numbers of studies on the release of small molecule drugs from polyurethanes and 
proteins from biodegradable polyurethanes for treating different diseases (Kim and Hollinger 2012, 
Saha, Butola et al. 2014).  However, few studies have investigated delivery of biological peptides 
from polyurethane matrices. In this study, we aimed to understand how therapeutic peptides might 
be incorporated and released from TPU films. We investigated a range of molecular weight peptides, 
which have different biological targets. Interestingly, we found there was a correlation between the 
cumulative release and molecular weight of the peptides. The systems we developed show the 
limitation for release of large molecule peptides. The physical formats of TPUs in this study were 
square films and disks. For the development of drug delivery systems rather than merely for implant 
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approach, changing the format of TPU to nanoparticles may promote the release of large molecule 
peptides due to the increase in surface area. More sophisticated TPU-based delivery systems should 
be designed for large molecule peptides. 
 
The reason why we chose C5aR antagonists as model peptides is due to the crucial issue of 
biocompatibility caused by host responses to implanted devices. Host responses severely limit the 
application of many implanted devices. When biomaterials are implanted into human body, three 
major events may lead to an inflammatory response, including surgical injury, host responses to 
implanted biomaterials, and responses of implanted biomaterials to host. For example, Rao has 
shown that responses of macrophages to polymethylmethacrylate particles induced inflammation 
(Rao, Gibon et al. 2012). Another example showed that decreased mechanical properties of dermal 
graft segments after implantation contributed to more inflammation (Hilger, Walter et al. 2006). 
Because of the complement system acting as an important mediator of this inflammatory response, 
many studies emphasize the importance of developing complement compatible biomaterials to 
prevent adverse inflammatory reactions in vivo (Kourtzelis, Rafail et al. 2012, Sokolov, Hellerud et 
al. 2012). Therefore, we proposed that delivery of C5aR antagonists by thermoplastic polyurethanes 
may be an effective strategy to minimize biomaterial-induced complement-mediated inflammatory 
responses, which may further prolong the performance of the implanted devices.  
 
First, we examined the stability of peptides under conventional polyurethane solvent casting 
conditions. The cyclic peptides were more stable in harsh conditions compared to linear peptides. 
Similar to the results of model drugs release (Chapter 3), the in vitro release of peptides shows that 
the extent and rate of peptide release were dependent on the composition of hard and soft segments 
in the TPUs. To control the release of peptides, existing biomedical grade TPUs with different hard 
and soft segments could be blended for treating different diseases.   
 
On the basis of the in vitro efflux release, peptide bonds between the amino acids in peptides might 
form hydrogen binding with the urethane linkage in polyurethanes, which may be similar to the beta 
sheet structure of proteins. The number of the H-binding may affect the efflux of the peptides. Long 
sequence peptides with more peptide bonds (-NH-CO-) might be released slower from TPUs than 
short peptides, as more H-binding will be formed. To design drug delivery systems, peptides with 
different lengths could be conjugated with therapeutic small molecule drugs for use as a controlled 
release system. The efflux of these small molecule drugs might be controlled by modifying the 
interaction between peptides and TPUs. Specifically, when a small molecule drug is conjugated 
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with peptides, the efflux of the drug with shorter peptide will be faster than for drug conjugated 
with longer peptides. Multi-drugs could also be conjugated with different lengths peptides 
depending on the requirement of treating diseases. If this were the case, on-demand drug delivery 
systems could be designed. These peptides with different lengths could be engineered to contain a 
specific enzymatic cleavage site to release the active small molecule drug. On-demand release could 
be triggered depending on the response of these peptides to the specific enzyme. 
 
Further investigation is required to understand how these systems we developed improve the in vivo 
pharmacokinetics and pharmacodynamics of peptides. PMX53 may be a good active C5aR 
antagonist for further drug delivery due to its stability in serum. For in vivo studies, we specifically 
investigated the delivery of peptide C5aR antagonist PMX53 using Tecoflex and 50% Tecoflex-50% 
ElastEon as matrices. 
 
6.3 Physiological based pharmacokinetics and pharmacodynamics of therapeutic 
peptides released from polyurethane films using a mouse model 
Understanding pharmacokinetics and pharmacodynamics of therapeutic peptide using in vivo 
animal model may improve the prediction of drug efficacy and safety in humans (Danhof, de Lange 
et al. 2008). For drug delivery systems, the pharmacokinetics and pharmacodynamics of a drug are 
governed not only by the drug physicochemical properties, but also by the properties of the drug 
delivery systems (Stepensky 2014). The design of appropriate delivery systems for therapeutic 
peptides is not essentially different from the systems for conventional small molecule drugs.  
 
However, for therapeutic peptides, several additional challenges should be considered, including 
poor stability in biological fluids, limited biomembrane permeability and rapid clearance and 
elimination (Breimer 1992). Improving the stability of peptides in biological fluids can be achieved 
by chemical modification (Patel, Cholkar et al. 2014), encapsulation into or conjugation with 
nanoparticles (Lalatsa, Schatzlein et al. 2014). Biomembrane permeability of peptides could be 
enhanced by incorporation with nanoparticles (Chalasani, Russell-Jones et al. 2007) or cell 
penetrating peptides (Bolhassani 2011). Among these challenges, rapid clearance and short 
elimination of peptides still severely limit their application as drug candidates. Due to their 
enormous potential as therapeutic agents, it is essential to develop safe and effective peptide 
delivery systems to extend their therapeutic efficacy. For example, a novel delivery platform was 
developed using anti-hapten antibody as peptide carrier to extend the in vivo half-life of an anti-
sepsis therapeutic peptide (WKYMVm-NH2) and retain its therapeutic efficacy (Park, Kim et al. 
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2014). Although the delivery system they developed was not able to control the release of peptides, 
this study provides relevant information in feasibility of using delivery systems to optimize peptides 
therapeutic efficacy. Therefore, in this study, we investigated the effect of TPU-based peptide 
delivery systems we developed in controlled release and enhancing therapeutic efficacy in vivo. 
 
The pharmacokinetic assessment of PMX53 was based on quantification of PMX53 concentration 
in plasma, and calculation and analysis of the major pharmacokinetic parameters. Interestingly, we 
found that the PMX53 plasma level was detectable over 9 days when released from blended 
Tecoflex-ElastEon (Figure 5.3, Chapter 5), while rapid elimination (half-life was 0.17 h) was found 
following i.p. administration (Figure 5.2, Chapter 5). The physiological based pharmacokinetics of 
PMX53 released from TPU films was determined by many factors, including diffusion of PMX53 
from TPU films, interaction of PMX53 with hard and soft segments of TPUs, and physicochemical 
properties of PMX53. These properties contribute greatly to designing appropriate delivery systems. 
 
Based on the in vivo pharmacokinetics assessment of PMX53 released from TPU films, it is 
possible to predict the PMX53 therapeutic effect profiles. In this study, we evaluated the 
pharmacological responses of released peptide by studying its effect on melanoma tumor growth. 
Studies have shown that inflammation caused by implantation of biomaterials promoted cancer cells 
recruitment (Ko, Wu et al. 2012). Recent studies have also shown that PMX53 was able to impair 
tumor growth following repetitive injection (Markiewski, DeAngelis et al. 2008, Nunez-Cruz, 
Gimotty et al. 2012). We therefore asked whether PMX53 released from the TPU delivery system 
we develop could retain bioactivity, impair inflammation-related tumor growth and avoid frequent 
administration. The results indicated that PMX53 released from blended TPUs was able to retain 
their bioactivity and prolong its therapeutic effect. 
 
In summary, the research presented in this thesis shows that TPU-based peptide delivery systems 
were able to control the efflux of peptides both in vitro and in vivo, and improve therapeutic 
efficacy in vivo. This study provides important findings for TPU-based therapeutic peptide delivery 
and these peptide-loaded polyurethanes could improve the pharmacological utility of peptides as 
therapeutics. For therapeutic peptides, more sophisticated delivery systems with on-demand release 
should be developed to further improve the efficacy and safety of therapeutic peptides. The trend of 
designing on-demand delivery systems, which release peptides only when needed, would be a major 
benefit to individual patient. 
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